<SEC-DOCUMENT>0001144204-18-022333.txt : 20180425
<SEC-HEADER>0001144204-18-022333.hdr.sgml : 20180425
<ACCEPTANCE-DATETIME>20180425153329
ACCESSION NUMBER:		0001144204-18-022333
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		6
CONFORMED PERIOD OF REPORT:	20180425
FILED AS OF DATE:		20180425
DATE AS OF CHANGE:		20180425

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-31062
		FILM NUMBER:		18774229

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>tv492020_6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Form 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Report of Foreign Private Issuer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Pursuant to Rule&nbsp;13a-16 or 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the month of April 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Commission File Number 000-31062</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 14pt"><B>Oncolytics
Biotech Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>(Translation of registrant&rsquo;s name
into English)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Suite 210, 1167 Kensington Crescent NW</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Calgary, Alberta, Canada T2N 1X7</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>(Address of principal executive offices)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will
file annual reports under cover Form&nbsp;20-F or Form&nbsp;40-F.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 49%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">Form&nbsp;20-F&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&thorn;</FONT></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">Form&nbsp;40-F&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">o</FONT></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant
is submitting the Form&nbsp;6-K in paper as permitted by Regulation&nbsp;S-T Rule&nbsp;101(b)(1):&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">o</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note: </B>Regulation&nbsp;S-T Rule&nbsp;101(b)(1)
only permits the submission in paper of a Form&nbsp;6-K if submitted solely to provide an attached annual report to security holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant
is submitting the Form&nbsp;6-K in paper as permitted by Regulation&nbsp;S-T Rule&nbsp;101(b)(7):&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">o</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note: </B>Regulation&nbsp;S-T Rule&nbsp;101(b)(7)
only permits the submission in paper of a Form&nbsp;6-K if submitted to furnish a report or other document that the registrant
foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated,
domiciled or legally organized (the registrant&rsquo;s &ldquo;home country&rdquo;), or under the rules of the home country exchange
on which the registrant&rsquo;s securities are traded, as long as the report or other document is not a press release, is not required
to be and has not been distributed to the registrant&rsquo;s security holders, and, if discussing a material event, has already
been the subject of a Form&nbsp;6-K submission or other Commission filing on EDGAR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 15%; border-bottom: black 2.25pt double; text-align: center"><FONT STYLE="font-size: 10pt"><B>EXHIBIT NO.</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 84%; border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt"><B>DESCRIPTION</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management Information Circular dated March 27, 2018, relating to the annual general meeting of the shareholders to be held on May 3, 2018</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Oncolytics Biotech Inc.</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Registrant)</P></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Date:&nbsp;&nbsp;April 25, 2018</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: Black 0.5pt solid">/s/&nbsp;&nbsp;Kirk Look</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Kirk Look</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Financial Officer</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tv492020_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 273px; width: 624px"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">NOTICE OF ANNUAL GENERAL MEETING</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">OF SHAREHOLDERS TO BE HELD ON MAY 3,
2018</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- AND -</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">MANAGEMENT INFORMATION CIRCULAR</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">March 27, 2018</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Table of Contents</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Page</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="width: 90%; text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_001">NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS</A></TD>
    <TD STYLE="width: 10%; text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#a_001">1</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_002">MANAGEMENT INFORMATION CIRCULAR</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#a_002">2</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_003">APPOINTMENT OF PROXY HOLDERS</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#a_003">2</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_004">REVOCABILITY OF PROXY</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#a_004">3</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_005">SIGNING OF PROXY</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#a_005">3</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_006">VOTING OF SHARES REPRESENTED BY MANAGEMENT PROXIES</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#a_006">3</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_007">VOTING SHARES AND THE PRINCIPAL HOLDERS OF COMMON SHARES</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#a_007">3</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_008">ADVICE TO BENEFICIAL HOLDERS OF COMMON SHARES</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#a_008">4</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_009">BUSINESS OF THE MEETING</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#a_009">5</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_010">COMPENSATION DISCUSSION AND ANALYSIS</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#a_010">9</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_011">DIRECTOR COMPENSATION</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#a_011">14</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_012">EQUITY COMPENSATION PLAN INFORMATION</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#a_012">16</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_013">SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#a_013">21</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_014">TERMINATION AND CHANGE OF CONTROL BENEFITS</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#a_014">21</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_015">PENSION PLAN BENEFITS</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#a_015">22</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_016">INDEBTEDNESS OF DIRECTORS AND SENIOR OFFICERS</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#a_016">22</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_017">INTEREST OF INFORMED PERSONS IN MATERIAL TRANSACTIONS</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#a_017">22</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_018">INTERESTS OF CERTAIN PERSONS OR COMPANIES IN MATTERS TO BE ACTED UPON</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#a_018">22</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_019">STATEMENT OF CORPORATE GOVERNANCE PRACTICES</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#a_019">22</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_020">ADDITIONAL INFORMATION</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#a_020">26</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 0pt; padding-left: 0in"><A HREF="#a_021">SCHEDULE&nbsp;A - MANDATE OF THE BOARD OF DIRECTORS</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#a_021">A-1</A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<IMG SRC="image_003.jpg" ALT=""></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="a_001"></A>NOTICE
OF ANNUAL GENERAL MEETING OF SHAREHOLDERS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>TO THE SHAREHOLDERS OF ONCOLYTICS BIOTECH&reg;&nbsp;INC.:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NOTICE IS HEREBY GIVEN that the annual
general meeting (the &ldquo;<B>Meeting</B>&rdquo;) of shareholders of Oncolytics Biotech&nbsp;Inc. (the &ldquo;<B>Corporation</B>&rdquo;)
will be held at the Toronto Region Board of Trade, First Canadian Place, Suite 350 &ndash; 77 Adelaide Street West, Toronto, Ontario
M5X 1C1 on May 3, 2018 at 4:30 p.m. (Toronto time). The purpose of the meeting is to consider, and to take action with respect
to, the following matters:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.</FONT></TD><TD STYLE="text-align: justify">to receive the audited financial statements of the Corporation for the year ended December 31,
2017, together with the auditors&rsquo; report thereon;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">2.</FONT></TD><TD STYLE="text-align: justify">to fix the number of directors of the Corporation for the ensuing year at seven&nbsp;(7);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">3.</FONT></TD><TD STYLE="text-align: justify">to elect the directors of the Corporation for the ensuing year;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">4.</FONT></TD><TD STYLE="text-align: justify">to appoint auditors for the Corporation for the ensuing year and the authorization of the directors
to fix their remuneration; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">5.</FONT></TD><TD STYLE="text-align: justify">to transact such other business as may properly be brought before the Meeting or any adjournment
or adjournments thereof.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Shareholders are referred to the accompanying
management information circular dated March 27, 2018 (the &ldquo;<B>Circular</B>&rdquo;) for more detailed information with respect
to the matters to be considered at the Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A shareholder may attend the Meeting in
person or may be represented at the Meeting by proxy. Shareholders who are unable to attend the Meeting in person are requested
to date, sign and return the accompanying Instrument of Proxy, or other appropriate form of proxy, in accordance with the instructions
set forth in the Circular. An Instrument of Proxy will not be valid unless it is deposited at the offices of Computershare Trust
Company of Canada, Proxy Department, 100&nbsp;University Avenue, 8<SUP>th</SUP>&nbsp;Floor, Toronto, Ontario M5J&nbsp;2Y1. Proxies
may also be faxed. Faxes may be forwarded to 1-866-249-7775 for calls within Canada and the U.S. or to 416-263-9524 for calls outside
Canada and the U.S. To be accepted, the proxy must be received by 4:30 p.m. (Toronto time) on May 1, 2018 which is two days (excluding
Saturdays, Sundays and holidays) before the Meeting, or if the Meeting is adjourned, by 4:30 p.m. (Toronto time) on the day which
is two days (excluding Saturdays, Sundays and holidays) before the date of the adjourned Meeting. A person appointed as proxyholder
need not be a shareholder of the Corporation. Only persons registered as holders of common shares on the records of the Corporation
as of the close of business on March 27, 2018 are entitled to receive notice of the Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">DATED as of the 27<SUP>th</SUP> day of
March, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 46%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 54%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt"><B>BY ORDER OF THE BOARD OF DIRECTORS</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">(signed) <I>Dr.&nbsp;Matthew C. Coffey</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt"><I>President and Chief Executive Officer</I></FONT></TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_004.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ONCOLYTICS BIOTECH&nbsp;INC.<BR>
210, 1167&nbsp;Kensington Crescent NW<BR>
Calgary, Alberta T2N&nbsp;1X7</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="a_002"></A>MANAGEMENT
INFORMATION CIRCULAR</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Except where indicated otherwise, the
following information is dated as at March 27, 2018 and all dollar amounts are in Canadian dollars.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SOLICITATION OF PROXIES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The information contained in this Management
Information Circular (the &ldquo;Circular&rdquo;) is furnished in connection with the solicitation of proxies by the management
of Oncolytics Biotech&nbsp;Inc. (&ldquo;Oncolytics&rdquo; or the &ldquo;Corporation&rdquo;) to be used at the annual general meeting
(the &ldquo;Meeting&rdquo;) of the holders (the &ldquo;Shareholders&rdquo;) of common shares (&ldquo;Common Shares&rdquo;) of the
Corporation to be held at the Toronto Region Board of Trade, First Canadian Place, Suite 350 &ndash; 77 Adelaide Street West, Toronto,
Ontario M5X 1C1 on May 3, 2018 at 4:30 p.m. (Toronto time), and at any adjournments or postponements thereof, for the purposes
set forth in the Notice of Meeting accompanying this Circular (the &ldquo;Notice of Meeting&rdquo;) and in this Circular</B>. Solicitation
of proxies will be primarily by mail, but may also be undertaken by way of telephone, facsimile or oral communication by the directors,
officers and regular employees of the Corporation, at no additional compensation. Costs incurred in the preparation and mailing
of this Information Circular and related materials and the costs associated with the solicitation of proxies will be borne by the
Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="a_003"></A>APPOINTMENT
OF PROXY HOLDERS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Matthew C. Coffey and Kirk J.&nbsp;Look
(the management designees named in the accompanying Instrument of Proxy) are both officers of the Corporation. <B>Each Shareholder
has the right to appoint a person (who does not need to be a Shareholder) other than Dr. Matthew C. Coffey or Kirk J.&nbsp;Look
to attend and to act for the Shareholder and on behalf of the Shareholder at the Meeting. To exercise this right, the names of
the nominees of management should be crossed out on the accompanying Instrument of Proxy and the Shareholder should insert the
name of the Shareholder&rsquo;s appointee in the blank space provided on the Instrument of Proxy or complete another appropriate
form of proxy.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A form of proxy will not be valid unless
it is deposited at the offices of Computershare Trust Company of Canada, Proxy Department, 100&nbsp;University Avenue, 8<SUP>th</SUP>&nbsp;Floor,
Toronto, Ontario, M5J&nbsp;2Y1. Proxies may also be faxed. Faxes may be forwarded to 1-866-249-7775 for calls within Canada and
the U.S. or to 416-263-9524 for calls outside Canada and the U.S. To be accepted, the proxy must be received by 4:30 p.m. (Toronto
time) on May 1, 2018 which is two days (excluding Saturdays, Sundays and holidays) before the Meeting, or if the Meeting is adjourned,
by 4:30 p.m. (Toronto time) on the day which is two days (excluding Saturdays, Sundays and holidays) before the date of the adjourned
Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="a_004"></A>REVOCABILITY
OF PROXY</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A Shareholder who has submitted a form
of proxy may revoke it at any time prior to the exercise thereof. A form of proxy may be revoked by the Shareholder personally
attending at the Meeting and voting his or her Common Shares. In addition to revocation in any other manner permitted by law, a
proxy may be revoked by an instrument in writing executed by the Shareholder or by his or her duly authorized attorney in writing
or, if the Shareholder is a corporation, under its corporate seal or executed by a duly authorized officer or attorney of the corporation
and deposited either at the registered office of the Corporation, being McCarthy T&eacute;trault&nbsp;LLP, 4000, 421&nbsp;&ndash;&nbsp;7<SUP>th</SUP>
Avenue&nbsp;S.W., Calgary, Alberta, T2P&nbsp;4K9, Attention: Michael Bennett, at any time up to and including the last business
day preceding the day of the Meeting, or any adjournment thereof, at which the form of proxy is to be used, or with the Chairman
of the Meeting on the day of the Meeting or any adjournment thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="a_005"></A>SIGNING
OF PROXY</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Instrument of Proxy must be signed
by the Shareholder or the Shareholder&rsquo;s duly appointed attorney authorized in writing or, if the Shareholder is a corporation,
by a duly authorized officer or attorney. An Instrument of Proxy signed by a person acting as attorney or in some other representative
capacity (including a representative of a corporate Shareholder) should indicate that person&rsquo;s capacity (following his or
her signature) and should be accompanied by the appropriate instrument evidencing qualification and authority to act (unless such
instrument has previously been filed with the Corporation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="a_006"></A>VOTING
OF SHARES REPRESENTED BY MANAGEMENT PROXIES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All Common Shares represented at the Meeting
by properly executed proxies will be voted on any ballot that may be called for and, where a choice with respect to any matter
to be acted upon has been specified in the Instrument of Proxy, the Common Shares represented by the proxy will be voted in accordance
with such instructions. The management designees named in the accompanying Instrument of Proxy will vote or withhold from voting
the Common Shares in respect of which they are appointed in accordance with the direction of the Shareholder appointing them on
any ballot that may be called for at the Meeting. <B>In the absence of such direction, the Common Shares will be voted FOR approval
of: (i)&nbsp;the fixing of the number of directors at seven (7) for the ensuing year; (ii)&nbsp;the election of directors; (iii)&nbsp;the
reappointment of the Corporation&rsquo;s current auditors, at such remuneration as may be determined by the board of directors
of the Corporation; and (iv)&nbsp;such other matters that may come before the Meeting, all as more particularly described in this
Information Circular. The accompanying Instrument of Proxy also confers discretionary authority upon the persons named therein
with respect to amendments of, or variations to, the matters identified in the Notice of Meeting and with respect to other matters
that may properly be brought before the Meeting. At the time of printing this Circular, the management of the Corporation knows
of no such amendment, variation or other matter to come before the Meeting other than the matters referred to in the Notice of
Meeting.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="a_007"></A>VOTING
SHARES AND THE PRINCIPAL HOLDERS OF COMMON SHARES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Voting of Common
Shares - General</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The record date for the purpose of determining
holders of Common Shares is March 27, 2018 (the &ldquo;<B>Record Date</B>&rdquo;). Shareholders of record on that date are entitled
to receive notice of and attend the Meeting and vote at the Meeting on the basis of one vote for each Common Share held, except
to the extent that: (i)&nbsp;a registered Shareholder has transferred the ownership of any Common Shares subsequent to the Record
Date; and (ii)&nbsp;the transferee of those Common Shares produces properly endorsed share certificates, or otherwise establishes
that he or she owns the Common Shares and demands, not later than April 24, 2018, which is ten calendar days before the Meeting,
that his or her name be included on the Shareholder list before the Meeting, in which case the transferee shall be entitled to
vote his or her Common Shares at the Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation is authorized to issue
an unlimited number of Common Shares. As at March 27, 2018, there are 142,325,222 Common Shares issued and outstanding. At the
Meeting, upon a show of hands, every Shareholder present in person or represented by proxy and entitled to vote shall have one
vote. On a poll or ballot, every Shareholder present in person or by proxy has one vote for each Common Share of which such Shareholder
is the registered holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When any Common Share is held jointly by
several persons, any one of them may vote at the Meeting in person or by proxy in respect of such Common Share, but if more than
one of them are present at the Meeting in person or by proxy and such joint owners of the proxy so present disagree as to any vote
to be cast, the joint owner present or represented whose name appears first in the register of Shareholders maintained by Computershare
Trust Company of Canada is entitled to cast such vote.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Quorum for the Meeting</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the Meeting, a quorum shall consist
of two persons present in person holding or representing by proxy not less than 5% of the votes attached to all outstanding Common
Shares. If a quorum is not present at the Meeting within one half hour after the time fixed for the holding of the Meeting, it
shall stand adjourned to such day being not less than 21&nbsp;days later and to such place and time as may be determined by the
Chairman of the Meeting. At such Meeting, the Shareholders present either in person or by proxy shall form a quorum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Principal Holders
of Common Shares</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the knowledge of the directors and executive
officers of the Corporation, as at the date hereof, no persons or companies beneficially own, directly or indirectly, or exercise
control or direction over, shares that carry more than 10% of the voting rights attached to the issued Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="a_008"></A>ADVICE
TO BENEFICIAL HOLDERS OF COMMON SHARES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The information set forth in this section
is for Shareholders who do not hold their Common Shares in their own name</B>. Shareholders who do not hold their Common Shares
in their own name (referred to in this Information Circular as &ldquo;<B>Beneficial Shareholders</B>&rdquo;) should note that only
proxies deposited by Shareholders whose names appear on the records of the Corporation as the registered holders of Common Shares
can be recognized and acted upon at the Meeting. If the Common Shares are listed in an account statement provided to a Shareholder
by a broker, then in almost all cases those shares will not be registered in the Shareholder&rsquo;s name on the records of the
Corporation. Such Common Shares will more likely be registered under the names of the Shareholder&rsquo;s broker or an agent of
that broker. In Canada, the vast majority of such Common Shares are registered under the name of CDS&nbsp;&amp;&nbsp;Co. (the registration
name for CDS&nbsp;Clearing and Depository Services Inc., which acts as nominee for many Canadian brokerage firms). Common Shares
held by brokers or their agents or nominees can only be voted (for or against resolutions) upon the instructions of the Beneficial
Shareholder. Without specific instructions, brokers and their agents and nominees are prohibited from voting shares for the broker&rsquo;s
clients. The Corporation does not know for whose benefit the Common Shares registered in the name of CDS&nbsp;&amp;&nbsp;Co. are
held. <B>Beneficial Shareholders cannot be recognized at the Meeting for the purposes of voting the Common Shares in person or
by proxy except as set forth below. Therefore, Beneficial Shareholders should ensure that instructions respecting the voting of
their Common Shares are communicated to the appropriate person.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Applicable regulatory policy requires intermediaries/brokers
to seek voting instructions from Beneficial Shareholders in advance of Shareholders&rsquo; meetings. Every intermediary/broker
has its own mailing procedures and provides its own return instructions to clients, which should be carefully followed by Beneficial
Shareholders in order to ensure that their Common Shares are voted at the Meeting. The purpose of the voting instruction form supplied
to a Beneficial Shareholder by its broker (or the agent of the broker) is limited to instructing the registered Shareholder (the
broker or agent of the broker) how to vote on behalf of the Beneficial Shareholder. The majority of brokers now delegate responsibility
for obtaining instructions from clients to Broadridge Financial Solutions&nbsp;Inc. (&ldquo;<B>Broadridge</B>&rdquo;). Broadridge
typically mails a voting instruction form to the Beneficial Shareholders and asks Beneficial Shareholders to return the voting
instruction forms to Broadridge, in the United States and Canada. Alternatively, Beneficial Shareholders can either call their
toll free telephone number to vote their Common Shares or access Broadridge&rsquo;s dedicated voting website at www.proxyvote.com
to deliver their voting instructions. Broadridge then tabulates the results of all instructions received and provides appropriate
instructions respecting the voting of Common Shares to be represented at the Meeting. <B>A Beneficial Shareholder receiving a voting
instruction form from Broadridge cannot use that voting instruction to vote shares directly at the Meeting, as the voting instruction
form must be returned to Broadridge well in advance of the Meeting in order to have the Common Shares voted.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Although a Beneficial Shareholder may not
be recognized directly at the Meeting for the purposes of voting Common Shares registered in the name of his or her broker (or
agent of the broker), a Beneficial Shareholder may attend at the Meeting as proxyholder for the registered Shareholder and vote
the Common Shares in that capacity. Beneficial Shareholders who wish to attend at the Meeting and indirectly vote their Common
Shares as proxyholder for the registered Shareholder should enter their own names in the blank space on the Instrument of Proxy
provided to them and return the same to their broker (or the broker&rsquo;s agent) in accordance with the instructions provided
by such broker (or agent), well in advance of the Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="a_009"></A>BUSINESS
OF THE MEETING</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> Item 1 - Consolidated Financial Statements and Auditors&rsquo; Report</P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The audited financial statements for the
financial year ended December 31, 2017 of the Corporation together with the auditors&rsquo; report thereon have been delivered
to the Shareholders. No formal action will be taken at the Meeting to approve the financial statements. If any Shareholder has
questions respecting the December 31, 2017 financial statements, the questions may be brought forward at the Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Item 2 - Fixing
Number of Directors of the Corporation</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The articles of the Corporation provide
for a minimum of 3&nbsp;directors and a maximum of 11&nbsp;directors. There are currently seven&nbsp;(7) directors. At the Meeting,
Shareholders will vote, by ordinary resolution, to fix the number of directors of the Corporation at seven (7). Approval of the
ordinary resolution in respect of this matter requires the affirmative vote of a majority of the votes cast in respect thereof
by the holders of Common Shares represented at the Meeting. <B>It is the intention of the persons named in the enclosed Instrument
of Proxy, if not expressly directed to the contrary in such Instrument of Proxy, to vote such proxies FOR the ordinary resolution
to fix the number of directors at seven (7).</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Item 3 - Election
of Directors</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the Meeting, seven (7) directors are
to be elected. If, prior to the Meeting, any vacancies occur in the slate of proposed nominees herein submitted, the persons named
in the enclosed Instrument of Proxy intend to vote FOR the election of any substitute nominee or nominees recommended by management
of the Corporation and FOR the remaining proposed nominees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The term of office for each director of
the Corporation is from the date of the Shareholders&rsquo; meeting at which he or she is elected until the next annual meeting
of the Shareholders or until his or her successor is elected or appointed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All of the nominees are now members of
the Board and have been since the dates indicated below. The term of each current director&rsquo;s appointment will expire at the
Meeting. <B>It is the intention of the persons named in the enclosed Instrument of Proxy, if not expressly directed to the contrary
in such Instrument of Proxy, to vote such proxies FOR the election of each of the nominees specified below as directors of the
Corporation. </B>Management of the Corporation does not contemplate that any of the nominees will be unable to serve as a director,
but if that should occur for any reason at or prior to the Meeting, the persons named in the enclosed form of proxy reserve the
right to vote for another nominee in their discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth for all
persons proposed to be nominated by management for election as directors, their province/state and country of residence, the positions
and offices with the Corporation now held by them, their present principal occupation and principal occupation for the preceding
five years, the periods during which they have served as directors of the Corporation and the number of Common Shares of the Corporation
beneficially owned, directly or indirectly, by each of them, or over which they exercise control or direction as of March 27, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 29%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B>Name, Municipality of <BR>
Residence and Date <BR>
Appointed a Director</B></TD>
    <TD STYLE="vertical-align: bottom; width: 51%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B>Present Principal Occupation and Principal <BR>
Occupation for Preceding Five Years</B></TD>
    <TD STYLE="vertical-align: top; width: 20%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B>Number of <BR>
Common Shares<BR>
 beneficially owned <BR>
and controlled<SUP>(1)</SUP></B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Deborah M. Brown, B.Sc., M.B.A.<SUP>(2)(3)</SUP></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>Ontario, Canada</I></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Director since November 2, 2017</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: justify">In addition to being a Management Consultant since 2014, Ms. Brown is currently the Managing Partner at Accelera CANADA, a specialty consultancy firm that assists emerging biopharma ventures in the United States and Europe with the development and implementation of Canadian market strategies. She held progressively senior roles at EMD Serono from 2000 to 2014, including Executive Vice President of Neuroimmunology for the company's U.S. operations, and President and Managing Director of the company's Canadian operations. In 2012, Ms. Brown was Chair of the Canadian National Pharmaceutical Organization (now Innovative Medicines Canada) and served on its Board of Directors from 2007 to 2014. She currently sits on the Boards of Life Sciences Ontario, the Strategic Executive Advisory Council for Canadian Cancer Trials Group, and her local SPCA. Ms. Brown holds an MBA from University of Western Ontario's Ivey School of Business, an Hons B.Sc. from the University of Guelph and completed the Merck executive development programme at the University of Hong Kong, INSEAD and Northwestern University's Kellogg School of Management.</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center">Nil</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; text-align: left">Matthew C. Coffey, Ph.D.<BR>
<I>Alberta</I>, <I>Canada</I><BR>
Director since May&nbsp;11, 2011</TD>
    <TD STYLE="vertical-align: bottom; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: justify">A co-founder of the Company, Dr. Coffey has been the President and Chief Executive Officer of the Company since January 2017. Dr. Coffey completed his doctorate degree in oncology at the University of Calgary with a focus on the oncolytic capabilities of the reovirus. The results of his research have been published in various respected scientific journals, including Science, Human Gene Therapy, and The EMBO Journal. Dr. Coffey has held the positions of Interim President and Chief Executive Officer from November 2016 to January 2017.&nbsp;&nbsp;Chief Operating Officer of the Company since December 2008, Chief Scientific Officer from December 2004 to December 2008, Vice-President of Product Development from July 1999 to December 2004 and Chief Financial Officer from September 1999 to May 2000.</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center">288,550</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; text-align: left">Angela Holtham,<SUP>(2)(3)</SUP><BR>
MBA, FCPA, FCMA, ICD.D<BR>
<I>Ontario, Canada</I><BR>
Director since June&nbsp;18, 2014</TD>
    <TD STYLE="vertical-align: bottom; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: justify">Ms. Holtham held a number of financial positions over a 19-year career with the Canadian subsidiary of Nabisco Inc., rising to become Senior Vice President and Chief Financial Officer. Then in 2002, she joined Toronto, Ontario-based Hospital for Sick Children as Vice President, Finance and Chief Financial Officer, a position she held for eight years. Through her career she has participated in many initiatives ranging from traditional finance functions and operations oversight to intellectual property portfolio management and mergers and acquisitions. Ms. Holtham is an FCPA, FCMA, holds an MBA from the University of Toronto and has completed the Institute of Corporate Directors Designation (ICD.D). Ms. Holtham holds a number of board and audit committee positions in both private and public sectors, including audit committee chair and director of Jamieson Wellness Inc.</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center">30,000</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; width: 29%"><B>Name, Municipality of <BR>
Residence and Date <BR>
Appointed a Director</B></TD>
    <TD STYLE="vertical-align: bottom; border-top: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; width: 51%"><B>Present Principal Occupation and Principal <BR>
Occupation for Preceding Five Years</B></TD>
    <TD STYLE="vertical-align: top; border-top: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; width: 20%"><B>Number of <BR>
Common Shares<BR>
 beneficially owned and controlled<SUP>(1)</SUP></B></TD></TR>
</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border: Black 1pt solid; padding-top: 3pt; text-align: left; width: 29%">J. Mark Lievonen<SUP>(2)(4)</SUP><BR>
CM, FCPA, FCA, LLD<BR>
<I>Ontario, Canada</I><BR>
Director since April&nbsp;5, 2004</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: justify; width: 51%; border-top: Black 1pt solid">Mr. Lievonen held the position of President of Sanofi Pasteur Limited, a vaccine development, manufacturing and marketing company, from 1999 to 2016. He is a Director of Acerus Pharmeceuticals Corporation, Quest PharmaTech Inc., and the Gairdner Foundation. Mr. Lievonen has served on a number of industry and not-for-profit boards including as the chair of Rx&amp;D (now Innovative Medicines Canada), BIOTECanada, and the Markham Stouffville Hospital Foundation, as Vice-Chair of the Ontario Institute for Cancer Research, as a Director of the Public Policy Forum, and as a Governor of York University Mr. Lievonen was appointed to the Order of Canada in 2015, &nbsp;named a Chevalier de l'Ordre National de M&eacute;rite by the government of France in 2007, and inducted into the Canadian Healthcare Marketing Hall of Fame in 2013.</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center; width: 20%; border-top: Black 1pt solid">23,000</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; text-align: left">Wayne Pisano, MBA<SUP>(2)(3)(6)</SUP><BR>
<I>New Jersey, USA</I><BR>
Director since May&nbsp;9, 2013</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: justify">Mr. Pisano has more than 30 years of experience as a pharmaceutical industry executive and was recognized in 2010 as Pharma Executive of the Year by the World Vaccine Congress. Mr. Pisano is the former president and CEO of Sanofi Pasteur, one of the largest vaccine companies in the world. He is credited with driving Sanofi Pasteur's leadership within the worldwide influenza market and capturing 50 percent of global sales. He also laid the foundation for the company's global pediatric vaccines strategy. During his tenure as CEO, Mr. Pisano bolstered the Sanofi Pasteur pipeline with the acquisitions of Acambis PLC, a bio-tech based in Boston in 2008 and Shantha Biotechnics, a highly regarded Indian vaccine company in 2010. Prior to joining Sanofi Pasteur, he spent 11 years with Novartis (formerly Sandoz). He has a bachelor's degree in biology from St. John Fisher College, New York and an MBA from the University of Dayton, Ohio. Mr. Pisano is a Board director and Chairman of the compensation and Governance Committee for Immunovaccine; a biotech based in Halifax.</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center">20,000</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; text-align: left">William G Rice, Ph.D.<SUP>(4)(5)</SUP><BR>
<I>California, USA</I><BR>
Director since June&nbsp;8, 2015</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: justify">Dr. Rice holds the position of Chairman, President and Chief Executive Officer of Aptose Biosciences Inc. since 2013. Also, from 2003 to present, he has served as Chairman, President and Chief Executive Officer of Cylene Pharmaceutics Inc., prior to which he was the Founder, President, Chief Executive Officer and Director of Achillion Pharmaceuticals, Inc. He served as Senior Scientist and Head of the Drug Mechanism Laboratory at the National Cancer Institute-Frederick Cancer Research and Development Center, and as a faculty member in the Division of Pediatric Hematology and Oncology at Emory School of Medicine. Dr. Rice holds a PhD in biochemistry from Emory University and was a post-doctoral trainee in the Department of Internal Medicine, Division of Hematology and Oncology at the University of Michigan Medical Center.</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center">Nil</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; width: 29%"><B>Name, Municipality of<BR>
 Residence and Date <BR>
Appointed a Director</B></TD>
    <TD STYLE="vertical-align: bottom; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; width: 51%"><B>Present Principal Occupation and Principal <BR>
Occupation for Preceding Five Years</B></TD>
    <TD STYLE="vertical-align: top; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; width: 20%"><B>Number of <BR>
Common Shares <BR>
beneficially owned and controlled<SUP>(1)</SUP></B></TD></TR>
</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; text-align: left; width: 29%">Bernd R. Seizinger, M.D.,<BR>
Ph.D.<SUP>(3)(5)</SUP><BR>
<I>New Jersey, USA and Munich, Germany</I><BR>
Director since June&nbsp;8, 2015</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: justify; width: 51%">Dr. Seizinger is currently Chairman and/or Board member of a number of biotech companies in the U.S. and Europe, including: Oxford BioTherapeutics Ltd., CryptoMedicx Inc., Opsona Ltd., Aprea AB, and Vaccibody AS. From 1998 to 2009, he served as President and Chief Executive Officer of GPC Biotech. He also served as Vice President of Oncology Drug Discovery and, in parallel, Vice President of Corporate and Academic Alliances at Bristol-Myers Squibb in Princeton, NJ. Prior to his appointments in the biotechnology and pharmaceuticals sectors, Dr. Seizinger held professorships and senior staff appointments at Harvard Medical School, Princeton University and Massachusetts General Hospital.</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; text-align: center; width: 20%">Nil</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notes:</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt; color: #010000">(1)</FONT></TD><TD STYLE="text-align: justify">The information as to the number of Common Shares beneficially owned, not being within the knowledge
of the Corporation, has been furnished by the respective nominees.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt; color: #010000">(2)</FONT></TD><TD STYLE="text-align: justify">Member of the Audit Committee. Ms.&nbsp;Holtham is Chair of this Committee.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt; color: #010000">(3)</FONT></TD><TD STYLE="text-align: justify">Member of the Compensation Committee. Mr. Pisano is Chair of this Committee.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt; color: #010000">(4)</FONT></TD><TD STYLE="text-align: justify">Member of the Governance Committee. Mr.&nbsp;Lievonen is Chair of this Committee.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt; color: #010000">(5)</FONT></TD><TD STYLE="text-align: justify">Member of the Science and Technology Committee. Dr.'s Rice and Seizinger serve as Co-Chairs of
this Committee.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt; color: #010000">(6)</FONT></TD><TD STYLE="text-align: justify">Mr. Pisano, as Chair of the Board, serves as an ex-officio member of the Governance and Science
and Technology Committees.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Majority Voting
Policy</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board has adopted a Majority Voting
Policy which relates to the election of directors. This policy requires that any nominee for director who, on a ballot taken on
the election of directors, has a greater number of votes withheld from voting than the number of votes received for his or her
election shall tender his or her resignation to the Chair and to the President, subject to acceptance by the Board. The policy
does not apply in circumstances involving contested director elections. The Board is required to consider the resignation, having
regard to the best interests of the Corporation and all factors considered relevant and to: (i)&nbsp;accept the resignation; (ii)&nbsp;maintain
the director but address what the Board believes to be the underlying cause of the withhold votes; or (iii)&nbsp;reject the resignation.
The Board is required to make its decision and announce it in a press release within 90&nbsp;days of the annual meeting, including,
if applicable, the reasons for rejecting a resignation offer. A director who is required to tender a resignation under the policy
will not participate in the deliberations of the Board with respect to his or her resignation unless there are fewer than three
directors who are not required to tender a resignation, in which event the entire Board will proceed in making the determination.
To the extent that the Board accepts one or more director resignations, the Board will also determine whether to fill any vacancy
prior to the next meeting of the shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Corporate Cease
Trade Orders or Bankruptcies</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None of the above proposed directors are,
or within 10&nbsp;years prior to the date of this Circular have been, a director, chief executive officer or chief financial officer
of any company that, while such person was acting in that capacity, was subject to a cease trade order, an order similar to a cease
trade order or an order that denied the relevant issuer access to any exemption under securities legislation, that was in effect
for a period of more than 30&nbsp;consecutive days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None of the above proposed directors are,
or within 10&nbsp;years prior to the date of this Circular have been, a director, chief executive officer or chief financial officer
of any company that was subject to a cease trade order, an order similar to a cease trade order or an order that denied the relevant
issuer access to any exemption under securities legislation, that was in effect for a period of more than 30 consecutive days,
that was issued after the proposed director ceased to be a director, chief executive officer or chief financial officer and which
resulted from an event that occurred while that person was acting in the capacity as director, chief executive officer or chief
financial officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None of the above proposed directors are,
or within 10&nbsp;years prior to the date of this Circular have been, a director or executive officer of any company that, while
acting in that capacity, or within a year of that person ceasing to act in that capacity, became bankrupt, made a proposal under
any legislation relating to bankruptcy or insolvency or was subject to or instituted any proceedings, arrangement or compromise
with creditors or had a receiver, receiver manager or trustee appointed to hold its assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Personal Bankruptcies</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None of the above proposed directors have,
within 10&nbsp;years prior to the date of this Circular, become bankrupt, made a proposal under any bankruptcy or insolvency legislation,
been subject to or instituted any proceedings, arrangement or compromise with creditors or had a receiver, receiver manager or
trustee appointed to hold their assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Penalties and Sanctions</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None of the above proposed directors have
been subject to any penalties or sanctions imposed by a court relating to securities legislation or by a securities regulatory
authority or have entered into a settlement agreement with a securities regulatory authority, or any other penalties or sanctions
imposed by a court or regulatory body that would likely be considered important to a reasonable securityholder in deciding whether
to vote for the proposed director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Item 4 - Appointment
and Remuneration of the Auditors</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation has requested that Ernst&nbsp;&amp;&nbsp;Young&nbsp;LLP,
Chartered Accountants of Calgary, Alberta act as independent auditors for the Corporation subject to Shareholder approval. <B>It
is the intention of the persons named in the enclosed Instrument of Proxy, if not expressly directed to the contrary in such Instrument
of Proxy, to vote such proxies FOR the ordinary resolution to appoint the firm of Ernst&nbsp;&amp;&nbsp;Young&nbsp;LLP, Chartered
Accountants, as auditors of the Corporation to hold office until the close of the next annual meeting of Shareholders or until
the firm of Ernst&nbsp;&amp;&nbsp;Young&nbsp;LLP, Chartered Accountants is removed from office or resigns as provided by law or
by the Corporation&rsquo;s by-laws, and to authorize the directors of the Corporation to fix the remuneration of Ernst&nbsp;&amp;&nbsp;Young&nbsp;LLP,
Chartered Accountants, as auditors of the Corporation.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="a_010"></A>COMPENSATION
DISCUSSION AND ANALYSIS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation has formed a compensation
committee (the &ldquo;<B>Compensation Committee</B>&rdquo;) which consists of four outside, independent directors, Dr. Seizinger,
Ms. Holtham, Ms. Brown, and Mr. Pisano, the Chair of the Board. Mr. Pisano is the Chair of the Compensation Committee. No member
of the Compensation Committee has been an employee officer of the Corporation or any of its affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The objectives of the Corporation&rsquo;s
compensation arrangements are: (i)&nbsp;to attract and retain key personnel; (ii)&nbsp;to encourage commitment to the Corporation
and its goals; (iii)&nbsp;to align executive interests with those of its shareholders; and (iv)&nbsp;to reward executives for performance
in relation to overall corporate progress goals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The key elements of the compensation program
are the base salary, health benefits, and payments allocated to employees to be directed by them to their personal retirement accounts.
Bonuses and the granting of Options (as defined herein) and Share Awards (as defined herein) are also part of the Corporation&rsquo;s
compensation program and are based on corporate performance. Part of corporate performance includes goals and objectives that are
determined based on the strategic planning and budgeting process, which is conducted at least annually. The elements of the compensation
plan are intended to reward performance, and the various elements are intended to provide a blend of short-term and long-term incentives
to align the interests of management and the shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In arriving at its recommendations for
compensation, the Compensation Committee considers the long-term interests of the Corporation as well as its current stage of development
and the economic environment within which it operates. The market for biotechnology companies in the development phase is challenging.
Based on these factors, the Compensation Committee recognized the need to strike a balance between compensation to retain employees
and resources expended to maintain operations. In the past, the Compensation Committee has engaged specialist consultants to assist
in benchmarking its compensation practices and provide recommendations to the committee with respect to compensation for directors
and officers. In 2017, the Compensation Committee engaged Radford, An Aon Hewitt Company as a specialist consultant to assist with
the benchmarking of officer compensation for 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following a review of the risks in the
Corporation&rsquo;s compensation policies and practices, the Compensation Committee found no risks that are reasonably likely to
have a material adverse effect on the Corporation. The Compensation Committee&rsquo;s role of approving the compensation policies
and practices includes considering whether the compensation policies and practices could encourage a Named Executive Officer (as
defined below) to take inappropriate or excessive risks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Corporation&rsquo;s corporate
trading policy, insiders (including Named Executive Officers and directors) are not permitted to hedge their position in Common
Shares, Options, Share Awards, deferred share units, performance share units, debentures or other debt instruments by use of any
financial instrument, which would include but is not limited to options, puts, calls, warrants or short sells, designed to benefit
the holder from a change in the market value of the Common Shares of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For 2017, the following guidelines were
employed by the Board in granting bonuses, Options and Share Awards to the Corporation&rsquo;s executive and senior officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Annual Bonus, Option
Grants and Share Award Grants</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For 2017, the Chief Executive Officer of
the Corporation is eligible for a cash bonus of up to 40% of his base salary, the Chief Financial Officer and the Chief Medical
Officer are each eligible for a cash bonus of up to 35% of his base salary and the other senior officers are eligible for a cash
bonus of up to 15 to 25% of their respective base salaries. In addition, when available, the officers are eligible for a combination
of Option and Share Award grants. The amount of each grant is determined and approved by the Board with the actual bonus provided
and the number of Options and Share Awards granted based upon the overall performance of the Corporation as assessed by the Compensation
Committee and approved by the Board. The overall performance of the Corporation is determined by the annual goals and objectives
approved by the Board and includes specific objectives with respect to the clinical, manufacturing, and intellectual property plans
in combination with financial goals. Previous grants are taken into account when considering new grants of Options and Share Awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For 2018, similar guidelines are expected
to be applied except the cash bonus target for the Chief Executive Officer will increase to up to 50% of base salary and for the
Chief Financial Officer and Chief Medical Officer the cash bonus target will increase to up to 40% of base salary. For the other
senior officers the cash bonus target will increase to up to 30% of base salary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Performance Graph</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following graph and table compare the
change in the cumulative total shareholder return on the Common Shares over the period from December&nbsp;31, 2012 to December
31, 2017 (assuming a $100&nbsp;investment was made on December&nbsp;31, 2012) with the cumulative total return of the S&amp;P/TSX
Capped Health Care Index over the same period, assuming reinvestment of dividends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As outlined in the compensation discussion
and analysis, the Compensation Committee balances the various short-term and long-term objectives and provides bonuses and Options
and Share Awards based on performance against these objectives. The movement in share price based upon one index is not considered
wholly representative of the actions to be taken regarding compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 289px; width: 481px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD NOWRAP STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Dec 31,<BR>
 2013</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD NOWRAP STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Dec 31,<BR>
 2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD NOWRAP STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Dec 31, <BR>
2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD NOWRAP STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Dec 31, <BR>
2016</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD NOWRAP STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Dec 31,<BR>
 2017</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; font-size: 10pt; text-align: justify; padding-left: 3pt">Oncolytics Biotech Inc.</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">100.00</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">38.55</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">23.19</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">15.96</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">42.77</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 3pt">S&amp;P/TSX Capped Health Care Index</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">100.00</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">119.01</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">146.43</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">81.37</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">112.04</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Compensation Governance</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Compensation Committee exercises general
responsibility for the Corporation&rsquo;s human resources and compensation policies and processes. Among other responsibilities,
the Compensation Committee reviews and makes recommendations to the Board regarding the amount of regular and incentive compensation
to be paid to the Chief Executive Officer and the amounts of regular and incentive compensation to be paid to certain designated
executives after considering the Chief Executive Officer&rsquo;s assessment of the performance of such executives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each member of the Compensation Committee
is an independent director and is ineligible to participate in any of the Corporation&rsquo;s executive officer compensation programs,
other than the Stock Option Plan (as defined herein) and the Share Award Plan (as defined herein). Each member has extensive director
and officer experience with various public and private companies in the design and implementation of executive compensation plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Compensation Advisors
and Executive Compensation-Related Fees</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Compensation Committee, from time to
time, engages specialist consultants to assist in benchmarking its compensation practices and provide recommendations to the committee
with respect to compensation for directors and officers, however, no such consultant was retained in 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Summary Compensation
Table</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth all compensation
paid, payable, awarded, granted, given, or otherwise provided, directly or indirectly, by the Corporation, or a subsidiary of the
Corporation, in Canadian dollars, to the individuals who were, at December 31, 2017, the Chief Executive Officer, the Chief Financial
Officer and the next three most highly compensated executive officers whose total compensation was, individually, more than $150,000,
and such other individuals as required (collectively, the &ldquo;<B>Named Executive Officers</B>&rdquo;) of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="white-space: nowrap; font-size: 10pt; text-align: justify; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="5" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Non-equity incentive plan compensation<BR> ($)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; padding-left: 0; text-indent: 0">Name and principal<BR>
 position</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Salary<BR> ($)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Share-</B></FONT><BR> <FONT STYLE="font-size: 10pt"><B>based awards<SUP>(1)</SUP></B></FONT><BR> <FONT STYLE="font-size: 10pt"><B>($)</B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Option-</B></FONT><BR> <FONT STYLE="font-size: 10pt"><B>based</B></FONT><BR> <FONT STYLE="font-size: 10pt"><B>Awards<SUP>(1)</SUP></B></FONT><BR> <FONT STYLE="font-size: 10pt"><B>($)</B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Annual incentive plans<BR> ($)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Long-term incentive plans<BR> ($)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Pension value<BR> ($)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>All other compensation<SUP>(2)</SUP></B></FONT><BR> <FONT STYLE="font-size: 10pt"><B>($)</B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total compensation<BR> ($)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="white-space: nowrap; width: 12%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Dr. Matthew C. Coffey<SUP>(3)</SUP></FONT></TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; font-size: 10pt; text-align: right">2017</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; font-size: 10pt; text-align: right">430,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">N/A</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; font-size: 10pt; text-align: right">61,964</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; font-size: 10pt; text-align: right">172,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 7%; font-size: 10pt; text-align: center; padding-left: 3pt">N/A</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">N/A</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; font-size: 10pt; text-align: right">62,235</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; font-size: 10pt; text-align: right">726,199</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="white-space: nowrap; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">President and Chief Executive</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2016</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">406,714</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">125,400</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">101,678</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 3pt">N/A</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">N/A</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">59,674</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">693,466</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="white-space: nowrap; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">Officer</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2015</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">380,107</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">N/A</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">173,307</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">79,822</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 3pt">N/A</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">N/A</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">57,039</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">690,275</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="white-space: nowrap; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 3pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="white-space: nowrap; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">Kirk J. Look</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2017</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">345,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">N/A</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">46,473</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">120,750</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 3pt">N/A</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">N/A</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">55,223</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">567,446</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="white-space: nowrap; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">Chief Financial Officer</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2016</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">325,584</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">79,800</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">81,396</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 3pt">N/A</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">N/A</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">52,981</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">539,761</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="white-space: nowrap; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2015</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">319,200</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">N/A</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">109,556</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">67,032</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 3pt">N/A</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">N/A</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">52,014</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">547,802</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="white-space: nowrap; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 3pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="white-space: nowrap; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Dr. Andres A. Gutierrez<SUP>(4)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2017</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">376,350</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">N/A</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">N/A</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">131,723</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 3pt">N/A</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">N/A</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">35,482</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">543,555</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="white-space: nowrap; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">Chief Medical Officer</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2016</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">68,684</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">78,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">23,285</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 3pt">N/A</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">N/A</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6,354</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">176,323</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="white-space: nowrap; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2015</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">N/A</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">N/A</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">N/A</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">N/A</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 3pt">N/A</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">N/A</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">N/A</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">N/A</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="white-space: nowrap; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 3pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="white-space: nowrap; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Andrew de Guttadauro<SUP>(4)(5)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2017</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">144,267</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">31,200</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">38,487</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">72,134</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 3pt">N/A</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">N/A</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">13,815</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">299,903</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="white-space: nowrap; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">President, Oncolytics</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2016</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">N/A</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">N/A</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">N/A</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">N/A</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 3pt">N/A</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">N/A</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">N/A</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">N/A</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="white-space: nowrap; font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0; text-indent: 0">Biotech (U.S.) Inc.</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">2015</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">N/A</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">N/A</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">N/A</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">N/A</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-bottom: 1pt; padding-left: 3pt">N/A</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">N/A</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">N/A</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">N/A</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><BR>
Notes:</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 22.5pt"><FONT STYLE="color: #010000">(1)</FONT></TD><TD STYLE="text-align: justify">The value of share and option-based awards are based on the grant date assumptions as disclosed
in note 8 &ldquo;Share Based Payments&rdquo; in our 2017 audited consolidated financial statements.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 22.5pt"><FONT STYLE="color: #010000">(2)</FONT></TD><TD STYLE="text-align: justify">The dollar amounts set forth under this column are related to contributions to the officers&rsquo;
respective retirement savings plan and amounts provided for health care benefits by the Corporation.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 22.5pt"><FONT STYLE="color: #010000">(3)</FONT></TD><TD STYLE="text-align: justify">None of the compensation paid to Dr. Coffey related to his role as a director of the Corporation.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 22.5pt"><FONT STYLE="color: #010000">(4)</FONT></TD><TD STYLE="text-align: justify">US Employees are paid salaries, bonuses and other compensation in US Dollars. These amounts are
presented in Canadian dollars and have been converted at a US/CDN exchange rate of $1.2545, $1.3427 and $1.3840 for the years 2017,
2016 and 2015, respectively.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 22.5pt"><FONT STYLE="color: #010000">(5)</FONT></TD><TD STYLE="text-align: justify">Mr. de Guttadauro was appointed as President of Oncolytics Biotech (U.S.) Inc., a wholly-owned
subsidiary of the Corporation, on June 29, 2017.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Employment Agreements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation has entered into employment
agreements with each of the Named Executive Officers (the &ldquo;<B>Employment Agreements</B>&rdquo;, each an &ldquo;<B>Employment
Agreement</B>&rdquo;). Pursuant to the terms of the Employment Agreements, Dr.&nbsp;Coffey is entitled to an annual salary of $475,000
for the calendar year 2018, Mr.&nbsp;Look is entitled to an annual salary of $365,000 for the calendar year 2018, Dr. Gutierrez
is entitled to a salary of US$330,000 for the calendar year 2018 and Mr. de Guttadauro is entitled to an annual salary of US$253,000
for the calendar year 2018. Further, each Named Executive Officer is entitled to additional benefits and performance-based bonuses.
The Employment Agreements provide that each Named Executive Officer is subject to certain confidentiality and non-competition restrictions
during and following the course of their respective employment with the Corporation. Each Employment Agreement shall continue until
terminated by either party in accordance with the notice provisions thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Outstanding Share-Based
Awards and Option-Based Awards</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth for each
Named Executive Officer all option-based and share-based awards outstanding at December 31, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-size: 10pt; text-align: center; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="12" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Option-based Awards</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Share-based Awards</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; padding-left: 0; text-indent: 0">Name</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of securities underlying unexercised options<BR> (#)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Option exercise price<BR> ($)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Option expiration date</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Value of unexercised in-the-money options<SUP>(1)</SUP></B></FONT><BR> <FONT STYLE="font-size: 10pt"><B>($)</B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of shares or units of shares that have not vested<BR> (#)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Market or payout value of share-based awards that have not vested<BR> ($)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Market or payout value of vested share-based awards not paid out or distributed<BR> ($)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="width: 12%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">Dr. Matthew C. Coffey</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">30,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">3.06</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 12%; font-size: 10pt; text-align: center">Dec 8, 2019</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">Nil</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">330,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">234,300</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 11%; font-size: 10pt; text-align: center; padding-left: 0.5pt">Nil</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font-size: 10pt; text-align: justify; padding-left: 0; text-indent: 0"></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">115,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6.72</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Dec 14, 2020</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">Nil</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 0.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font-size: 10pt; text-align: justify; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">18,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4.31</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">July 27, 2021</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">Nil</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 0.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font-size: 10pt; text-align: justify; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">125,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3.89</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Dec 14, 2021</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">Nil</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 0.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font-size: 10pt; text-align: justify; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">125,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4.21</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Dec 17, 2022</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">Nil</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 0.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font-size: 10pt; text-align: justify; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">240,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1.74</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Dec 11, 2023</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">Nil</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 0.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font-size: 10pt; text-align: justify; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">734,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0.42</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Dec 1, 2025</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">212,860</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 0.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font-size: 10pt; text-align: justify; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">400,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0.28</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Jan 16, 2027</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">172,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 0.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="font-size: 10pt; text-align: justify; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 0.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font-size: 10pt; text-align: justify; padding-left: 0; text-indent: 0">Kirk J. Look</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">10,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3.06</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Dec 8, 2019</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">Nil</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">210,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">149,100</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 0.5pt">Nil</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">25,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6.72</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Dec 14, 2020</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">Nil</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 0.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font-size: 10pt; text-align: justify; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">35,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3.89</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Dec 14, 2021</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">Nil</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 0.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font-size: 10pt; text-align: justify; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">200,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2.00</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Nov 13, 2022</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">Nil</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 0.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font-size: 10pt; text-align: justify; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">40,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4.21</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Dec 17, 2022</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">Nil</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 0.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font-size: 10pt; text-align: justify; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">160,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1.74</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Dec 11, 2023</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">Nil</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 0.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font-size: 10pt; text-align: justify; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">464,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0.42</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Dec 1, 2025</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">134,560</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 0.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font-size: 10pt; text-align: justify; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">300,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0.28</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Jan 16, 2027</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">129,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 0.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="font-size: 10pt; text-align: justify; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 0.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font-size: 10pt; text-align: justify; padding-left: 0; text-indent: 0">Dr. Andres Gutierrez</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">150,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0.26</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Nov 10, 2026</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">67,500</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">300,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">213,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 0.5pt">Nil</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="font-size: 10pt; text-align: justify; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 0.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">Andrew de Guttadauro</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">125,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0.52</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">July 3, 2027</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">23,750</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">60,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">42,600</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 0.5pt">Nil</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-bottom: 1pt; padding-left: 0.5pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notes:</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 22.5pt"><FONT STYLE="font-size: 10pt; color: #010000">(1)</FONT></TD><TD STYLE="text-align: justify">These amounts are calculated based on the difference between the closing price of the securities
underlying the Options on the Toronto Stock Exchange (&ldquo;<B>TSX</B>&rdquo;) on December 29, 2017 ($0.71), and the exercise
price of the Options.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 22.5pt"><FONT STYLE="font-size: 10pt; color: #010000">(2)</FONT></TD><TD STYLE="text-align: justify">These amounts are calculated based on the closing price of the Common Shares on the TSX on December
29, 2017 ($0.71).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Value Vested or
Earned During the Year</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth for each
Named Executive Officer the value vested or earned on all option-based awards, share-based awards, and non-equity incentive plan
compensation during the financial year ending December 31, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; padding-left: 0; text-indent: 0">Name</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Option-based awards &ndash;<BR> Value vested during the year<BR> ($)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Share-based awards &ndash; <BR> Value vested during the year<BR> ($)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Non-equity incentive plan compensation &ndash; <BR> Value earned during the year<BR> ($)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 25%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">Dr. Matthew C. Coffey</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 22%; font-size: 10pt; text-align: right">130,875</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24%; font-size: 10pt; text-align: center; padding-left: 3pt">Nil</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24%; font-size: 10pt; text-align: center; padding-left: 3pt">N/A</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">Kirk J. Look</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">92.750</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 3pt">Nil</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 3pt">N/A</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">Dr. Andres Gutierrez</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">18,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 3pt">Nil</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 3pt">N/A</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0; text-indent: 0">Andrew de Guttadauro</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">Nil</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-bottom: 1pt; padding-left: 3pt">Nil</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-bottom: 1pt; padding-left: 3pt">N/A</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="a_011"></A>DIRECTOR
COMPENSATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Director Compensation
Table</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table details the compensation
received by each director of the Corporation in 2017 who is not a salaried employee of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; padding-left: 0; text-indent: 0">Name</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><B>Fees Earned</B><BR> <B>($)<SUP>(1)</SUP></B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><B>Share-Based Awards</B><BR> <B>($)<SUP>(2)</SUP></B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><B>Option-Based Awards</B><BR> <B>($)<SUP>(2)</SUP></B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Non-Equity Incentive Plan Compensation<BR> ($)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Pension Value<BR> ($)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">All Other Compensation<BR> ($)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total<BR> ($)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; width: 12%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">Deborah Brown<SUP>(3)</SUP></TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">17,249</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">25,278</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">14,666</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 12%; font-size: 10pt; text-align: center; padding-left: 3pt">Nil</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">N/A</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 11%; font-size: 10pt; text-align: center; padding-left: 3pt">Nil</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">57,193</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">Angela Holtham</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">53,003</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">82,275</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">Nil</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 3pt">Nil</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">N/A</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 3pt">Nil</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">135,278</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">Mark Lievonen</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">75,270</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">53,278</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">Nil</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 3pt">Nil</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">N/A</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 3pt">Nil</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">128,548</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">Wayne Pisano</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">75,270</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">92,770</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">Nil</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 3pt">Nil</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">N/A</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 3pt">Nil</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">168,040</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">William Rice</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">75,270</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">53,278</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">Nil</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 3pt">Nil</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">N/A</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 3pt">Nil</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">128,548</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0; text-indent: 0">Bernd Seizinger</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">30,108</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">99,164</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">Nil</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-bottom: 1pt; padding-left: 3pt">Nil</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">N/A</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-bottom: 1pt; padding-left: 3pt">Nil</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">129,272</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notes:</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(1)</FONT></TD><TD STYLE="text-align: justify">Directors are paid fees in US Dollars. These amounts are presented in Canadian dollars and have
been converted at a US/CDN exchange rate of $1.2545.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(2)</FONT></TD><TD STYLE="text-align: justify">The value of share based and option based awards are based on the grant date assumptions as disclosed
in note&nbsp;8 <I>&ldquo;Share Based Payments&rdquo;</I> in our 2017 audited consolidated financial statements.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(3)</FONT></TD><TD STYLE="text-align: justify">Ms. Brown was appointed as a director on November 2, 2017.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board has approved the following compensation
structure for the independent directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Annual Retainer </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each director receives a base retainer
of US$40,000. In addition to the base retainer directors are eligible to receive the following additional fees depending on committee
involvement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Additional Retainers (USD):</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 50%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%; font: 10pt Times New Roman, Times, Serif; text-align: justify">Board chair</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">40,000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Audit Committee chair</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">20,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Governance &amp; Compensation Comm.ittee chair</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Science &amp; Technology co-chair</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">15,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Non-chair member of the Audit Committee</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Non-chair member of the Governance or Compensation Committee</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Directors, annually, may opt to take up
to 100% of their respective annual retainer in RSAs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the combined retainer, the
Corporation will grant annually to each director $20,000 of RSAs that will vest over a three year period. The annual RSA grant
will be granted on or about October 1 of each year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation also grants to directors,
from time to time, Options (as defined herein) in accordance with the Stock Option Plan (as defined herein) and the reimbursement
of any reasonable expenses incurred by them while acting in their directors&rsquo; capacity. During the year ended December 31,
2017, total compensation of $746,879 was paid to the independent directors which consisted of fee payments of $326,170, share-base
awards of $406,043 and option-based awards of $14,666.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Outstanding Share-Based
Awards and Option Based Awards</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth for each
director, other than Named Executive Officers who are directors, all option-based and share-based awards outstanding at December
31, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-size: 10pt; text-align: justify; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="12" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Option-based Awards</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="9" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Share-based Awards</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; padding-left: 0; text-indent: 0">Name</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of securities underlying unexercised options<BR> (#)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Option exercise price<BR> ($)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Option expiration date</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Value of unexercised in-the-money options<SUP>(1)</SUP></B></FONT><BR> <FONT STYLE="font-size: 10pt"><B>($)</B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of shares or units of shares that have not vested<BR> (#)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Market or payout value of share-based awards that have not vested</B><SUP>(2)</SUP></FONT><BR> <FONT STYLE="font-size: 10pt"><B>($)</B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Market or payout value of vested share-based awards not paid out or distributed<BR> ($)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; width: 12%; font-size: 10pt; text-align: justify; padding-left: 0; text-indent: 0">Deborah Brown</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">50,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">0.57</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 12%; font-size: 10pt; text-align: center">Nov 7, 2027</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">7,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">37,729</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">26,788</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 11%; font-size: 10pt; text-align: center; padding-left: 0.5pt">Nil</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; font-size: 10pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Angela Holtham<SUP>(3)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">50,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1.46</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">June 18, 2024</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">Nil</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">313,498</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">222,584</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 0.5pt">Nil</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; font-size: 10pt; text-align: justify; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 0.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; font-size: 10pt; text-align: justify; padding-left: 0; text-indent: 0">Mark Lievonen</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">17,500</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3.06</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Dec 8, 2019</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">Nil</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">267,315</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">189,794</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 0.5pt">Nil</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; font-size: 10pt; text-align: justify; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">30,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6.72</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Dec 14, 2020</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">Nil</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 0.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; font-size: 10pt; text-align: justify; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">35,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3.89</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Dec 14, 2021</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">Nil</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 0.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; font-size: 10pt; text-align: justify; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">35,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4.21</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Dec 17, 2022</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">Nil</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 0.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; font-size: 10pt; text-align: justify; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">35,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1.74</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Dec 11, 2023</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">Nil</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 0.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; font-size: 10pt; text-align: justify; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 0.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; font-size: 10pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Wayne Pisano<SUP>(4)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">50,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2.89</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">May 9, 2023</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">Nil</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">438,311</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">311,201</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 0.5pt">Nil</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; font-size: 10pt; text-align: justify; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">30,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1.74</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Dec 11, 2023</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">Nil</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 0.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; font-size: 10pt; text-align: justify; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 0.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; font-size: 10pt; text-align: justify; padding-left: 0; text-indent: 0">William Rice</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">50,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0.80</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">June 8, 2025</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">Nil</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">267,315</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">189,794</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 0.5pt">Nil</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; font-size: 10pt; text-align: justify; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 0.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Bernd Seizinger<SUP>(5)</SUP></FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">50,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">0.80</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-bottom: 1pt">June 8, 2025</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">Nil</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">384,899</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">273,278</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-bottom: 1pt; padding-left: 0.5pt">Nil</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; font-size: 10pt; text-align: justify; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 0.5pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0"></P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> Notes:</P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="color: #010000">(1)</FONT></TD><TD STYLE="text-align: justify">These amounts are calculated based on the difference between the closing price of the Common Shares
on the TSX on December 29, 2017 ($0.71), and the exercise price of the options.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="color: #010000">(2)</FONT></TD><TD STYLE="text-align: justify">These amounts are calculated based on the closing price of the Common Shares on the TSX on December
29, 2017 ($0.71).</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="color: #010000">(3)</FONT></TD><TD STYLE="text-align: justify">Ms. Holtham elected to receive US$22,750 of her annual retainer in RSAs.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="color: #010000">(4)</FONT></TD><TD STYLE="text-align: justify">Mr.&nbsp;Pisano elected to receive US$20,000 of his annual retainer in RSAs.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="color: #010000">(5)</FONT></TD><TD STYLE="text-align: justify">Dr.&nbsp;Seizinger elected to receive US$36,000 of his annual retainer in RSAs.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Value Vested or
Earned During the Year</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth for each
director the value vested on all option-based awards, share-based awards, and value earned on non-equity incentive plan compensation
during the financial year ending December 31, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 25%; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; padding-left: 0; text-indent: 0">Name</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 24%; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; padding-left: 3pt">Option-based <BR>
awards - Value<BR>
 vested during the<BR>
 year<BR> ($)</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 24%; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; padding-left: 3pt">Share-based awards - <BR>
Value vested during the <BR>
year<BR> ($)</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 24%; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; padding-left: 3pt">Non-equity incentive plan<BR>
 compensation - Value earned during <BR>
the year<BR> ($)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-left: 0; text-indent: 0">Deborah Brown</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 3pt">Nil</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 3pt">Nil</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 3pt">N/A</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">Angela Holtham</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 3pt">Nil</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 3pt">Nil</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 3pt">N/A</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">Mark Lievonen</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 3pt">Nil</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 3pt">Nil</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 3pt">N/A</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">Wayne Pisano</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 3pt">Nil</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 3pt">Nil</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 3pt">N/A</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">William Rice</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 3pt">Nil</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 3pt">Nil</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 3pt">N/A</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0; text-indent: 0">Bernd Seizinger</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-bottom: 1pt; padding-left: 3pt">Nil</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-bottom: 1pt; padding-left: 3pt">Nil</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-bottom: 1pt; padding-left: 3pt">N/A</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="a_012"></A>EQUITY
COMPENSATION PLAN INFORMATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Stock Option Plan</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a summary of the Corporation&rsquo;s
Amended and Restated Stock Option Plan (the &ldquo;<B>Stock Option Plan</B>&rdquo;) dated effective as of May 4, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation, with the approval of its
Shareholders, has established the Stock Option Plan. The number of Common Shares reserved for issuance under the Stock Option Plan
and all other security based compensation arrangements of the Corporation (including the Share Award Plan) in aggregate shall not
exceed 10% of the total number of issued and outstanding Common Shares from time to time. As of March 27, 2018,9,065,567 Common
Shares, being approximately 6.37% of the outstanding Common Shares, are issuable pursuant to outstanding stock options (&ldquo;<B>Options</B>&rdquo;)
granted under the Stock Option Plan. As 2,709,067 Share Awards, representing approximately 1.90% of the outstanding Common Shares
as of March 27, 2018 have been granted under the Share Award Plan, an aggregate of 2,457,888&nbsp;Common Shares, being approximately
1.73% of the outstanding Common Shares are available for future grants of Options and Share Awards under the Stock Option Plan
and Share Award Plan as of March 27, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Stock Option Plan, the Board
of Directors or the Compensation Committee may from time to time designate directors, officers, employees of, or consultants to,
the Corporation or any subsidiary of the Corporation (such persons being &ldquo;<B>Eligible Persons</B>&rdquo;) to whom Options
may be granted and the number of Options to be granted to each.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Options may be exercised at a price (the
&ldquo;<B>Exercise Price</B>&rdquo;) which shall be fixed by the Board at the time the Option is granted. No Option can be granted
with an Exercise Price at a discount to the market, which shall be the closing price of the Common Shares on the stock exchange
upon which the Common Shares are listed on the first day preceding the date of grant on which at least one board lot of Common
Shares traded on such exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any Option shall be exercised or shall
expire or terminate for any reason without having been exercised in full, any Common Shares to which such Option relates shall
be available for the purposes of the granting of Options under the Stock Option Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The number of Shares that may be acquired
under an Option granted to a participant under the Stock Option Plan shall be determined by the Board as at the time the Option
is granted, provided that the aggregate number of Shares reserved for issuance to any one participant under the Stock Option Plan
or any other security based compensation arrangement of the Corporation, shall not exceed five percent (5%) of the total number
of issued and outstanding Common Shares (calculated on a non-diluted basis).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Without obtaining the approval of Shareholders
in accordance with the rules of the TSX or the requirements of any other stock exchange on which the Common Shares are then listed,
no Options shall be granted pursuant to the Stock Option Plan, if such grant together with grants pursuant to all other share compensation
arrangements of the Corporation, could result, at any time, in:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">a number of Common Shares issuable pursuant to Options granted to insiders exceeding ten percent
(10%) of the number of outstanding Common Shares at any time;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">the issuance within a one year period to insiders, of a number of Common Shares exceeding ten percent
(10%) of the number of outstanding Common Shares; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">the issuance to any one insider and such insider&rsquo;s associates, within a one year period,
of a number of Common Shares exceeding five percent (5%) of the number of outstanding Common Shares.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The value of Option grants to each non-employee
director shall not exceed $150,000 annually for any individual non-employee director (other than initial Option grants to new directors).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Options are generally granted for a term
expiring on the tenth anniversary of the date of grant and typically either vest immediately or as to one-third on each of the
first, second and third anniversary following the date of grant, as determined by the Board at the time the Option is granted.
Options are not transferable or assignable except to the person or persons to whom the participant&rsquo;s rights pass by the participant&rsquo;s
will or applicable law following the death or permanent disability of a participant. The Stock Option Plan provides that if the
expiration date of an Option occurs during a &ldquo;blackout period&rdquo; or within five (5) business days after a blackout period,
such expiration date shall be deemed to be extended to the date which is the tenth (10<SUP>th</SUP>) business day after the last
day of the applicable blackout period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to any written agreement between
the Corporation and a participant providing otherwise, if any participant shall cease to be an Eligible Person for any reason other
than the termination for cause or the death or permanent disability of the participant, such participant&rsquo;s Option will terminate
immediately as to the then unvested portion thereof and at 5:00 p.m. (Calgary time) on the earlier of the date of the expiration
of the applicable option period and the ninetieth (90<SUP>th</SUP>) day after the date such participant ceases to be an Eligible
Person as to the then vested portion of the Option. If a participant ceases to be an Eligible Person as a result of the termination
of such participant for cause, effective as of the date notice is given to the participant of such termination, all outstanding
Options shall be terminated and all rights to receive Common Shares thereunder shall be forfeited by such participant, and the
participant shall not be entitled to receive any Common Shares or other compensation in lieu thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to any written agreement between
the Corporation and a participant providing otherwise, if in the event of the death or permanent disability of a participant, any
Option previously granted to such participant shall be exercisable until the end of the applicable option period or until the expiration
of 12 months after the date of death or permanent disability of such participant, whichever is earlier, and then only: (i) by the
person or persons to whom the participant&rsquo;s rights under the Option shall pass by the participant&rsquo;s will or applicable
law; (ii) to the extent that he or she was entitled to exercise the Option as at the date of the participant&rsquo;s death or permanent
disability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding the foregoing, the Board
may, at its sole discretion, extend the period during which any Options may be exercised, in the case of Options held by non-employee
directors, by not more than one year, and in the case of Options held by other persons, by not more than three years, but in no
case longer than the normal expiry of the Options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of a change of control of
the Corporation (as such term is defined in the Stock Option Plan), all Options which have not otherwise vested in accordance with
their terms shall immediately vest and be exercisable, notwithstanding the other terms of the Options or the Stock Option Plan
for a period of time ending on the earlier of the expiry time of the Option and the ninetieth (90<SUP>th</SUP>) day following the
change of control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to any required approval of the
TSX and any other stock exchange on which the Common Shares are then listed, the Stock Option Plan and any Options granted thereunder
may be amended, modified or terminated by the Board without approval of any participant or Shareholder (provided that no such amendment
may be made that will materially prejudice the rights of any participant under any Option previously granted to the participant
without consent by such participant). Such changes may include, without limitation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">amending, modifying or terminating the Stock Option Plan with respect to all Common Shares in respect
of Options which have not yet been granted thereunder;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">making any amendment of a &ldquo;housekeeping nature&rdquo;;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">changing the provisions relating to the manner of exercise of Options;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">accelerating vesting or extending the expiration date of any Option (provided that such Option
is not held by an insider), provided that the period during which an Option is exercisable does not exceed 10 years from the date
the Option is granted;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">adding a cashless exercise feature, payable in cash or securities, whether or not providing for
a full deduction of the number of underlying Common Shares from the Stock Option Plan reserve; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(vi)</TD><TD STYLE="text-align: justify">making any addition to, deletion from or alteration of the provisions of the Stock Option Plan
or any Option that are necessary to comply with applicable law, the rules of the TSX, or the requirements of any other exchange
on which the Shares are then listed and to avoid unanticipated consequences deemed by the Board to be inconsistent with the purpose
of the Stock Option Plan.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding the foregoing, Shareholder
approval is required for any change to the Stock Option Plan or Options granted under it which:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(i)</FONT></TD><TD STYLE="text-align: justify">increases the number of Common Shares reserved for issuance under the Stock Option Plan;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(ii)</FONT></TD><TD STYLE="text-align: justify">extends eligibility to participate in the Stock Option Plan to persons other than Eligible Persons;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(iii)</FONT></TD><TD STYLE="text-align: justify">permits Options to be transferred, other than for normal estate settlement purposes or to an RRSP
or similar plan;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(iv)</FONT></TD><TD STYLE="text-align: justify">permits awards other than Options to be made under the Stock Option Plan;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(v)</FONT></TD><TD STYLE="text-align: justify">extends the term of an Option beyond the maximum expiry date set out in the Stock Option Plan (except
where an expiry date would have fallen within a blackout period;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(vi)</FONT></TD><TD STYLE="text-align: justify">reduces the exercise price of an Option, except for the purpose of maintaining Option value in
connection with a conversion, change, reclassification, redivision, redesignation, subdivision or consolidation of shares or a
reorganization, amalgamation, consolidation, merger, takeover bid or similar transaction involving the Corporation (for this purpose,
cancellation or termination of an Option prior to its expiry date for the purpose of reissuing Options to the same Option-holder
with a lower exercise price will be considered an amendment to reduce the exercise price of an Option);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(vii)</FONT></TD><TD STYLE="text-align: justify">changes the insider participation limitation at any time under the Stock Option Plan; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(viii)</FONT></TD><TD STYLE="text-align: justify">amends the amending provision of the Stock Option Plan.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation&rsquo;s annual burn rate
under the Stock Option Plan was 0.83% for the year ending December 31, 2017, 0.73% for the year ending December 31, 2016 and 2.91%
for the year ending December 31, 2015. For this purpose, the burn rate is calculated by dividing the total number of Options granted
during the applicable fiscal year divided by the weighted average number of Common shares outstanding for the applicable fiscal
year. The burn rate is subject to change, from time to time, based on the number of Options granted and the total number of Common
Shares issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Share Award Plan</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a summary of the Corporation&rsquo;s
Amended and Restated Incentive Share Award Plan (the &ldquo;<B>Share Award Plan</B>&rdquo;) dated effective as of May 4, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation, with the approval of its
Shareholders, has established the Share Award Plan. Under the Share Award Plan, the Board may, at such times and in such amounts
as the Board may deem advisable in its sole and absolute discretion, issue Performance Share Awards (&ldquo;<B>PSAs</B>&rdquo;)
to eligible employees, including officers, and Restricted Share Awards (&ldquo;<B>RSAs</B>&rdquo; and, together with PSAs, &ldquo;<B>Share
Awards</B>&rdquo;) to Eligible Persons. The number of Common Shares reserved for issuance under the Share Award Plan and all other
security based compensation arrangements of the Corporation (including the Stock Option Plan) in aggregate shall not exceed 10%
of the total number of issued and outstanding Common Shares from time to time. As of March 27, 2018, 900,000 PSAs and 1,809,067
RSAs, representing approximately 0.63% and 1.27%, respectively, of the outstanding Common Shares as of March 27, 2018 have been
granted under the Share Award Plan. As 9,065,567 Common Shares, being approximately 6.37% of the outstanding Common Shares, are
issuable pursuant to outstanding Options, an aggregate of 2,457,888 Common Shares, being approximately 1.73% of the outstanding
Common Shares are available for future grants of Options and Share Awards under the Stock Option Plan and the Share Award Plan
as of March 27, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to earlier vesting in accordance
with the terms of the Share Award Plan and unless otherwise determined by the Board, Share Awards granted under the Share Award
Plan vest on the third anniversary date of the date of grant. Upon vesting, each RSA is deemed to be redeemed for no further consideration
for one&nbsp;Common Share (subject to adjustment for dividend equivalents) and each PSA is deemed to be redeemed for no further
consideration for one&nbsp;Common Share (subject to adjustment for dividend equivalents) multiplied by the percentage (&ldquo;<B>Vesting
Percentage</B>&rdquo;) of outstanding PSAs that will vest based upon the relative achievement of any performance-related measures
or criteria as determined by the Board in its sole discretion, which may include the Corporation&rsquo;s performance compared to
identified operational or financial targets and the Corporation&rsquo;s shareholder return.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate number of Common Shares issuable
at any time to insiders, under all security based compensation arrangements of the Corporation shall not exceed 10% of the issued
and outstanding Common Shares (calculated on a non-diluted basis). The aggregate number of Common Shares issued pursuant to all
security based compensation arrangements of the Corporation, within a one year period, shall not exceed 10% of the issued and outstanding
Common Shares (calculated on a non-diluted basis). The Share Award Plan further provides that the aggregate number of Common Shares
reserved for issuance to any one participant under all security based compensation arrangements of the Corporation, shall not exceed
5% of the total number of issued and outstanding Common Shares (calculated on a non-diluted basis).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The maximum number of Common Shares that
may be reserved for issuance to non-employee directors pursuant to RSAs under the Share Award Plan is 1% of the Common Shares outstanding
at the time of the grant (on a non-diluted basis), less the aggregate number of Common Shares reserved for issuance to such non-employee
director under any other security based compensation arrangement, and the total annual grant of RSAs to any one non-employee director
cannot exceed a grant value of $150,000 (less the amount awarded to such non-employee director).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Share Award Plan provides that if the
issue date of any Share Award occurs during a blackout period, then the issue date for such Share Award shall not occur until the
date which is the tenth (10<SUP>th</SUP>) business day after the last day of the such blackout period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise determined by the Board
in its sole discretion, upon a Change of Control (as such term is defined in the Share Award Plan), all unvested Share Awards shall
become automatically vested (in the case of PSAs, with a deemed Vesting Percentage of 100). Common Shares issuable in respect of
Share Awards shall be, and shall be deemed to be, issued to participants effective immediately prior to the completion of the transaction
which would result in the Change of Control unless issued prior thereto in accordance with the Share Award Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise determined by the Board
or unless otherwise expressly set forth in a Share Award agreement pertaining to a particular Share Award or any written employment
or other agreement governing a participant&rsquo;s role as an Eligible Person if a participant ceases to be an Eligible Person
as a result of the termination of such participant for cause or if a participant voluntarily ceases to be an Eligible Person for
any reason other than as a result of the death, permanent disability or retirement of the participant, all outstanding Share Awards
Agreements under which Share Awards have been granted to such participant shall be terminated. Upon the death, permanent disability
or retirement of a participant (other than the early retirement of an eligible employees), all outstanding Share Awards shall immediately
vest. If a participant ceases to be an Eligible Person other than in the circumstances provided above, all Share Awards awarded
to such participant under any outstanding Share Awards shall fully vest effective as of the date of cessation of employment (the
&ldquo;<B>Cessation Date</B>&rdquo;), unless otherwise determined by the Board, and the participant shall be entitled to receive
the number of Common Shares equal to the number of Share Awards granted multiplied by a fraction (A) the numerator of which is
the number of days from the date of grant thereof to the Cessation Date; and (B) the denominator of which is the total number of
days during which such Share Award were scheduled to vest upon grant. In such circumstances, the Vesting Percentage in respect
of PSAs shall be determined as of the Cessation Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Share Award Plan and any Share Awards
granted thereunder may be amended, modified or terminated by the Board without approval of Shareholders, subject to any required
approval of the TSX. Such changes may include, without limitation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(i)</FONT></TD><TD STYLE="text-align: justify">amending, modifying or terminating the Share Award Plan with respect to all Common Shares in respect
of Share Awards which have not yet been granted thereunder;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(ii)</FONT></TD><TD STYLE="text-align: justify">making any amendment of a &quot;housekeeping nature&quot;; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(iii)</FONT></TD><TD STYLE="text-align: justify">making any addition to, deletion from or alteration of the provisions of this Plan or any Share
Award that are necessary to comply with applicable law, the rules of the TSX, or the requirements of any other stock exchange on
which the Common Shares are then listed and to avoid unanticipated consequences deemed by the Board to be inconsistent with the
purpose of this Plan.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding the foregoing, the Share
Award Plan or a Share Award may not be amended without shareholder approval to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(i)</FONT></TD><TD STYLE="text-align: justify">increase the number of Common Shares issuable pursuant to outstanding Share Awards at any time;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(ii)</FONT></TD><TD STYLE="text-align: justify">change the insider participation limit under the Share Award Plan;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(iii)</FONT></TD><TD STYLE="text-align: justify">expand the categories of individuals who are &ldquo;eligible employees&rdquo; who are eligible
to participate in the Share Award Plan;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(iv)</FONT></TD><TD STYLE="text-align: justify">extend the term of any Share Award beyond the term of such awards provided for under the terms
and conditions of the Share Award Plan;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(v)</FONT></TD><TD STYLE="text-align: justify">permit the transfer or assignment of Share Awards, except to permit a transfer to a family member,
an entity controlled by the holder of the Share Awards or a family member, a charity or for estate planning or estate settlement
purposes; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(vi)</FONT></TD><TD STYLE="text-align: justify">change the amendment provisions of the Share Award Plan.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, no amendment to the Share
Award Plan or any Share Awards granted pursuant thereto may be made without the consent of an Share Award Plan participant if it
adversely alters or impairs the rights of such participant in respect of any Share Award previously granted to such participant
under the Share Award Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation&rsquo;s annual burn rate
under the Share Award Plan was 0.83% for the year ending December 31, 2017, 1.67% for the year ending December 31, 2016 and 0.33%
for the year ending December 31, 2015. For this purpose, the burn rate is calculated by dividing the total number of Share Awards
granted during the applicable fiscal year divided by the weighted average number of Common shares outstanding for the applicable
fiscal year. The burn rate is subject to change, from time to time, based on the number of Share Awards granted and the total number
of Common Shares issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="a_013"></A>SECURITIES
AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation currently has two share
based compensation plans: the Stock Option Plan and the Share Award Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As at December 31, 2017, the only outstanding
Options, warrants and rights granted under an equity compensation plan were Options granted under the Stock Option Plan and Share
Awards granted under the Share Award Plan. The Common Shares available for issuance under such plans as at December 31, 2017 are
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; padding-left: 0; text-indent: 0">Plan category</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of Common Shares to be issued upon exercise of outstanding Options and Share Awards</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><B>Weighted-average exercise price of outstanding Options<SUP>(1)</SUP></B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of Common Shares remaining available for future issuance under equity compensation plans</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 55%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">Equity compensation plans approved by security holders</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">8,857,734</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">1.39</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">5,374,788</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0; text-indent: 0">Equity compensation plans not approved by security holders</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">N/A</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">N/A</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">N/A</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: justify; padding-bottom: 2.5pt; padding-left: 0; text-indent: 0">Total</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">8,857,734</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">1.39</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">5,374,788</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Note:</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt; color: #010000">(1)</FONT></TD><TD STYLE="text-align: justify">Relates to outstanding Options only.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See <I>&ldquo;Equity Compensation Plan
Information &ndash; Stock Option Plan&rdquo;</I> and <I>&ldquo;Equity Compensation Plan Information &ndash; Share Award Incentive
Plan&rdquo; </I>for particulars of the outstanding Options and Share Awards as at March 27, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="a_014"></A>TERMINATION
AND CHANGE OF CONTROL BENEFITS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Employment Agreements of the Named
Executive Officer are terminated by the Corporation other than for cause, Dr.&nbsp;Coffey, Mr.&nbsp;Look and Dr. Gutierrez shall
be entitled to 12&nbsp;months&rsquo; pay in lieu of notice and Mr. de Guttadauro shall be entitled to 6 months&rsquo; pay in lieu
of notice. If the Employment Agreements are terminated by the Corporation other than for cause, then all unexercised and unvested
Options then held by each are governed by the terms of the Stock Option Plan and all unvested Share Awards held by each are governed
by the terms of the Share Award Plan. Furthermore, if there is a change of control of the Corporation and Dr.&nbsp;Coffey, Mr.&nbsp;Look,
Dr. Gutierrez or Mr. de Guttadauro, are terminated without cause within one year following such change of control, then the terminated
employee shall be entitled to 24&nbsp;months&rsquo; pay in lieu of notice. Termination pay as discussed in this paragraph includes
payment in lieu of benefits that otherwise would have been earned during the applicable term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table reflects amounts payable
to the Named Executive Officers with termination without cause or change of control benefits, assuming that their employment was
terminated on December 31, 2017 without cause or due to a change of control of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; padding-left: 0; text-indent: 0">Name</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><B>Termination without Cause Severance<SUP>(1)</SUP></B><BR> <B>($)</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><B>Change of Control Severance<SUP>(2)</SUP></B><BR> <B>($)</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; font-size: 10pt; text-align: justify; padding-left: 0; text-indent: 0">Dr. Matthew C. Coffey</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">541,168</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">1,082,335</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-left: 0; text-indent: 0">Kirk J. Look, CA</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">422,093</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">844,185</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-left: 0; text-indent: 0">Dr. Andres Gutierrez<SUP>(3)</SUP></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">349,619</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">699,238</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 0; text-indent: 0">Andrew de Guttadauro<SUP>(3)</SUP></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">131,727</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">526,908</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notes:</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(1)</FONT></TD><TD STYLE="text-align: justify">As at December 31, 2017, all Options granted to the Named Executive Officers had fully vested,
except for the options granted on December 1, 2015, November 10, 2016 and July 3, 2017. As a result, all Named Executive Officers
shall be entitled to exercise all or any part of their vested Options, within the period ending on the earlier of the date of expiration
of the Option and the 90<SUP>th</SUP> day after the date such Named Executive Officer is terminated unless otherwise approved by
the Board of Directors.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(2)</FONT></TD><TD STYLE="text-align: justify">On a change of control of the Corporation, the Named Executive Officers shall be entitled to exercise
all or a part of their Options, whether vested or not, within the period ending on the earlier of the date of expiration of the
Option and the 90<SUP>th</SUP> day after the date such officer is terminated.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(3)</FONT></TD><TD STYLE="text-align: justify">US Employees are paid in US dollars and are presented in US&nbsp;dollars.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="a_015"></A>PENSION
PLAN BENEFITS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation does not provide pension
plan benefits to its Named Executive Officers and employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="a_016"></A>INDEBTEDNESS
OF DIRECTORS AND SENIOR OFFICERS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No director, officer or proposed nominee
for election as a director of the Corporation or any associate of any such persons is, or has been, indebted to the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="a_017"></A>INTEREST
OF INFORMED PERSONS IN MATERIAL TRANSACTIONS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are no material interests, direct
or indirect, of directors, proposed directors, senior officers, any shareholder who beneficially owns, directly or indirectly,
more than 10% of the outstanding Common Shares or any known associate or affiliates of such persons, any transaction within the
last financial year or in any proposed transaction which has materially affected or would materially affect the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="a_018"></A>INTERESTS
OF CERTAIN PERSONS OR COMPANIES IN MATTERS TO BE ACTED UPON</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management of the Corporation is not aware
of any material interest, direct or indirect, of any director or proposed nominee for director, or executive officer or anyone
who has held office as such since the beginning of the Corporation&rsquo;s last financial year or of any associate or affiliate
of any of the foregoing in any matter to be acted on at the Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="a_019"></A>STATEMENT
OF CORPORATE GOVERNANCE PRACTICES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board of Directors is responsible for
overseeing the management of the business and affairs of the Corporation. The Board of Directors is responsible for establishing
the Corporation&rsquo;s policy direction and fundamental objectives. The Board of Directors delegates to management the responsibility
and authority to direct the Corporation&rsquo;s day-to-day operations, subject to compliance with Board-approved budgets and strategic
plans. Certain matters, including the acquisition or development of new lines of business, divestments and long-term financing,
among other things, must be approved in advance by the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board of Directors discharges its responsibilities
through preparation for and attendance at regularly scheduled meetings, and through its committees. The Board of Directors reviews
and provides advice with respect to key strategic initiatives and projects, and reviews and assesses processes relating to long
range planning and budgeting. The Governance Committee assists the Board in matters pertaining to corporate values, beliefs and
standards of ethical conduct, as well as other corporate governance issues and the Audit Committee assists the Board in matters
pertaining to management information and internal control systems. The Board of Directors also monitors financial reports, the
conduct and results of the annual independent audit, finance and accounting policies and other financial matters. In addition,
the Audit Committee reviews and recommends to the Board for approval the Corporation&rsquo;s interim financial statements, and
also reviews and recommends the year-end audited financial statements for approval by the Board. The Board of Directors also has
a Compensation Committee, which is responsible for attracting, retaining and fairly compensating employees of the Corporation.
The Compensation Committee is also responsible for succession planning. Subject to limited exceptions, these committees generally
do not have decision-making authority. Rather, they convey their findings and make recommendations on matters falling within their
respective mandates to the full Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board of Directors supports the principle
that its membership should represent a diversity of backgrounds, experience and skills. The Board, through the Governance Committee,
reviews on an annual basis the appropriate characteristics of Board members in the context of the current composition of the Board
and the objectives and needs of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Composition of the
Board</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As at December 31, 2017, the Corporation
had seven (7) Board members. A majority of the directors of the Corporation are independent. The six (6) independent directors
of the Corporation were Deborah Brown, Angela&nbsp;Holtham, Mark&nbsp;Lievonen, Wayne&nbsp;Pisano, William&nbsp;Rice and Bernd&nbsp;Seizinger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The one director of the Corporation who
is not independent is Dr.&nbsp;Matthew C. Coffey, the President and Chief Executive Officer of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The directors of the Corporation who are
also directors of other reporting issuers are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 80%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 32%; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; text-align: justify"><B>Director</B></TD>
    <TD STYLE="width: 68%; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; text-align: justify"><B>Other Reporting Issuers</B></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-top: 3pt; padding-right: 5.75pt; padding-left: 5.75pt; text-align: justify">Angela Holtham</TD>
    <TD STYLE="vertical-align: bottom; padding-top: 3pt; padding-right: 5.75pt; padding-left: 5.75pt; text-align: justify">Jamieson Wellness Inc.</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-right: 5.75pt; padding-left: 5.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mark Lievonen</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD>
    <TD STYLE="padding-right: 5.75pt; padding-left: 5.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Acerus Pharmaceuticals Corporation;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Quest Pharma Tech Inc.</P></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 5.75pt; padding-left: 5.75pt; text-align: justify">Wayne Pisano</TD>
    <TD STYLE="padding-right: 5.75pt; padding-left: 5.75pt; text-align: justify">Immunovaccine Inc.</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; text-align: justify">William Rice</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; text-align: justify">Aptose Biosciences Inc.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr.&nbsp;Wayne&nbsp;Pisano, the Chair,
is an independent director. The principal responsibility of the Chair is to ensure the independence of the Board in the discharge
of its responsibilities. In this regard, the Chair, individually or with the support of the committees, consults with the President
and Chief Executive Officer on selection of committee members and committee chairs, Board meetings and planning meeting agendas,
the format and adequacy of information provided to directors and the effectiveness of Board meetings. The Chair also consults directly
with other directors on issues of Board independence or dissent, conflicts of interest of the President and Chief Executive Officer,
or personal liability matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Board Mandate</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The text of the Board&rsquo;s written mandate
is attached as Schedule &ldquo;A&rdquo; to this Circular.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Attendance at Meetings</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a summary of attendance
of the directors at meetings of the Board and its committees since January 1, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 16%; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; padding-left: 0; text-indent: 0">Director</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><B>Board</B></TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 16%; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; padding-left: 5.4pt">Audit Committee</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 16%; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; padding-left: 5.4pt">Governance Committee</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 16%; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; padding-left: 5.4pt">Compensation Committee</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 15%; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; padding-left: 5.4pt">Science &amp; Technology Committee</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-left: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Wayne Pisano<SUP>(1)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">7 of 7</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 5.4pt">4 of 4</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 5.4pt">3 of 3</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 5.4pt">3 of 3</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 5.4pt">4 of 4</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-left: 0; text-indent: 0">Dr. Matt Coffey</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">7 of 7</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 5.4pt">N/A</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 5.4pt">N/A</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 5.4pt">N/A</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 5.4pt">N/A</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-left: 0; text-indent: 0">Mark Lievonen</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">7 of 7</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 5.4pt">4 of 4</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 5.4pt">3 of 3</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 5.4pt">N/A</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 5.4pt">N/A</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-left: 0; text-indent: 0">Angela Holtham</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">7 of 7</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 5.4pt">4 of 4</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 5.4pt">N/A</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 5.4pt">3 of 3</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 5.4pt">N/A</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-left: 0; text-indent: 0">William Rice</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">7 of 7</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 5.4pt">N/A</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 5.4pt">3 of 3</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 5.4pt">N/A</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 5.4pt">4 of 4</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-left: 0; text-indent: 0">Bernd Seizinger</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">7 of 7</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 5.4pt">N/A</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 5.4pt">N/A</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 5.4pt">2 of 3</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 5.4pt">4 of 4</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt; padding-left: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Deborah Brown<SUP>(2)</SUP></FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">2 of 3</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-bottom: 1pt; padding-left: 5.4pt">N/A</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-bottom: 1pt; padding-left: 5.4pt">N/A</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-bottom: 1pt; padding-left: 5.4pt">2 of 2</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-bottom: 1pt; padding-left: 5.4pt">N/A</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notes:</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(1)</FONT></TD><TD STYLE="text-align: justify">As Chair of the Board, Mr. Pisano is an ex-officio member of the Governance and Science and Technology
Committees, is a member of the Audit Committee and is Chair of the Compensation Committee.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(2)</FONT></TD><TD STYLE="text-align: justify">Ms. Brown was appointed as a director and a member of each of the Audit Committee and Compensation
Committee on November 2, 2017.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While the independent Board members do
not regularly schedule meetings at which neither non-independent directors or members of management are present, such independent
directors hold in camera sessions at each regularly scheduled Board meeting and the Board otherwise ensures open and candid discussion
among its independent directors by continuously monitoring situations where a conflict of interest or perceived conflict of interest
with respect to a director may exist. In cases where a conflict of interest or perceived conflict of interest is identified, it
is addressed in accordance with the ABCA and the Board&rsquo;s mandate. The Board may determine that it is appropriate to hold
in camera sessions excluding directors with a conflict of interest or perceived conflict of interest or such director may consider
that it is appropriate to recuse himself or herself from considering and voting with respect to the matter under consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Position Descriptions</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board has developed position descriptions
for the chair and the chair of each Board committee which delineate the role and responsibilities of these positions. The Board
and the Chief Executive Officer have developed a written position description for the Chief Executive Officer which delineates
the role and responsibilities of this position.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Orientation and
Continuing Education</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board provides new directors with the
Board and committee mandates and reviews these with the new Board members. The Board and management review the nature and operations
of the Corporation, initially upon appointment and continually through scheduled Board meetings and other sessions as required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board provides continuing education
for its Board members on issues relevant to the Corporation through Board interaction at Board meetings and ongoing communications
between scheduled meetings as required or requested.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Ethical Business
Conduct</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board has adopted a written code of
ethics for the directors, officers and employees of the Corporation. A copy of the code is available on the Corporation&rsquo;s
website www.oncolyticsbiotech.com. The Board satisfies itself regarding compliance with the code through its review of the activities
of the Corporation, discussions by the Audit Committee with the external auditors of the Corporation without management present,
and enquiries of management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board encourages and supports the exercise
of independent judgment by directors in considering transactions and agreements in respect of which a director or executive officer
has a material interest. The Board requires that any director or officer with a material interest in a transaction or agreement
under discussion disclose and declare their interest. The Board then conducts all discussions with respect to the transaction or
agreement without the interested director or officer present for the determination and precludes any interested director from voting
thereon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board encourages and promotes a culture
of ethical business conduct through its actions and its support and interaction with management and employees of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Nomination of Board
Members</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation identifies potential director
candidates through a search process that may include the use of an executive search firm. Qualifications of potential candidates
are reviewed and interviews are held by members of the Governance Committee with the potential candidates. The Governance Committee
makes recommendations to the Board with respect to new director candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Governance Committee is comprised entirely
of independent directors. The Governance Committee, in its capacity as the nominating committee, has the responsibility to present
the annual slate of directors to the Board for the Board&rsquo;s approval. Once approved by the Board, the proposed selection is
then presented to the Shareholders for their approval at the next scheduled annual meeting. During the year, this committee has
the responsibility of locating and recommending additional directors to fill vacancies or supplement the Board as required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Determination of
Compensation of Directors and Officers</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board has established a Compensation
Committee comprised entirely of independent directors. The Compensation Committee reviews and reports to the Board on director
and officer compensation issues. In determining the compensation for the directors, the committee assesses the directors&rsquo;
roles and responsibilities and an analysis of the competitive position of the Corporation&rsquo;s director compensation program,
including the ability to draw directors with the background and experience required to provide an effective Board. In determining
the compensation for officers, similar principles are applied and an independent compensation consultant is engaged from time to
time to provide additional relevant information to the Compensation Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further information regarding the activities
of the Compensation Committee is provided above under the heading &ldquo;<I>Compensation Discussion and Analysis</I>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Other Board Committees</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board has established four committees,
each of which is comprised entirely of independent directors. These committees are the Audit Committee, the Compensation Committee,
Governance Committee and Science &amp; Technology Committee. Mandates for the Board and each of the committees of the Board can
be found on the Corporation&rsquo;s website under &ldquo;Investor Center/Corporate Governance&rdquo; at www.oncolyticsbiotech.com/investor-centre/corporate-governance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Assessments of Directors
and the Board</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Through its Governance Committee, the Board
assesses, at least annually, the effectiveness and contribution of each member of the Board. The assessment is conducted through
dialogue with Board members and is part of the information used in setting the slate of directors to be proposed to the Shareholders
at the next annual meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Director Term Limits</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation actively encourages independent
board member renewal through its formal term limit policy, adopted on June&nbsp;30, 2015, whereby the independent director term
limit is set at 12&nbsp;years. Under the policy, the Board maintains the discretion to extend a directors&rsquo; term, if under
the circumstances, it is in the best interest of the Corporation and its shareholders. This in practice ensures that new independent
directors are appointed regularly, without losing the experience base of long serving directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Corporation&rsquo;s director
term limit policy, Mr. Lievonen&rsquo;s term is scheduled to expire at the Meeting, however, the Board has determined to exercise
its discretion to extend Mr. Lievonen&rsquo;s term as a director for an additional year as, in the circumstances, it has determined
that it is the best interests of the Corporation and its shareholders to do so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Policies Regarding
the Representation of Women on the Board</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While the Board recognizes the potential
benefits from new perspectives which could manifest through increased gender diversity within its ranks, the Board has not formally
adopted a written board diversity policy regarding the number or percentage of female members that it wishes to include on the
Board. The Board does not believe it is in the Corporation&rsquo;s interests to implement a written board diversity policy at this
time. The selection of candidates for appointment to the Board will continue to be based on the skills, knowledge, experience and
character of individual candidates and the requirements of the Board at the time, with achieving an appropriate level of diversity
on the Board being one of the criteria that the Governance Committee considers when evaluating the composition of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When considering candidates for senior
management positions, the Corporation focuses on attracting and retaining experienced and highly skilled individuals that can add
value to its business. Rather than considering the level of representation of women in executive officer positions when making
executive officer appointments, the Corporation considers all candidates based on their merit and qualifications relevant to the
specific role.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, while the Corporation recognizes
the benefits of diversity at all levels within its organization, the Corporation does not currently have any targets, rules or
formal policies that specifically require the identification, consideration, nomination or appointment of female board nominees
or candidates for executive management positions or that would otherwise force the composition of the Board or the Corporation&rsquo;s
executive management team. The Board does not believe it is in the Corporation&rsquo;s best interests to implement such targets
at this time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date hereof, there are two women
directors on the Board, representing 28.6% of the seven directors on the Board and 33.3% of the six independent directors on the
Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Director Shareholding
Requirements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board recognizes that share ownership
by members of the Board is a key element of strong corporate governance. The Board has adopted a director shareholding requirement
policy that each independent director will have purchased common shares on the open market, or hold RSAs, equal to one times the
director&rsquo;s base annual retainer. The value of each director&rsquo;s shareholdings will be based on the purchase price of
the common shares and the grant date value of any RSAs and will be reported to the Board at each regular meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="a_020"></A>ADDITIONAL
INFORMATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additional information relating to the
Corporation is available through the Internet on the Canadian System for Electronic Document Analysis and Retrieval (SEDAR) which
can be accessed at www.sedar.com. Financial information of the Corporation is provided in the comparative annual financial statements
and management&rsquo;s discussion and analysis of the Corporation for the most recently completed financial year. Copies of the
financial statements and management discussion and analysis of the Corporation may be obtained from the Chief Financial Officer
of the Corporation at Suite&nbsp;210, 1167&nbsp;Kensington Crescent&nbsp;N.W., Calgary, Alberta, T2N&nbsp;1X7 or by facsimile at
(403)&nbsp;283-0858.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_021"></A>SCHEDULE&nbsp;A<BR>
MANDATE OF THE BOARD OF DIRECTORS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
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M([1=(U64?VI OR.Q_P"/A!W_ -X=_7KZUZ37$_&#_DFNI?[T7_HQ:X'X ?\
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MN!^-GC'^S],3P_9R8N+M=]R5/*1=E_X$1^0]ZSO@CX,^]XEOH_6.R5A^#/\
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M%6X88[>&.&%%2.-0J*HP% X %/HHHIIJ&2O)OCLA.AZ4_87+C\U'^%8WP*D
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M/:7"AH9XVC=3W!&#7RWX5FDT/X@Z:0?F@OUB8^HW;6_0FOJNBOE6#_DI4?\
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MXXKLO GPAU[3]:M-6U&Z33OLSB18XV$DC>JG'R@$<'D_2O;:X_X@> (_'%G
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MZAIR#U#.W_LM:ME\"%# ZAK1([K!!C]6/]*ZW1_A7X8TDJ_V$WDH_CNFW_\
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M^..H263*T<.EK'=,AX\S>, ^^,?E3_"SJOQ4\:;F XM>I_V*?J/_ "6W2?\
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&11117__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $A >$# 2(  A$! Q$!_\0
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M 1?9+?\ YXI^5'V2W_YXI^5%M=V]Y&SVTR2HKM&Q0Y 8'!'U!J:@"'[);_\
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MC[);_P#/%/RHFN[>WM&NIYXX[=5W-([ *!ZYJ+3]4L-5@,^GWD-U$#@M$X8
M_A0!+]DM_P#GBGY4?9+?_GBGY55M=<TJ]OI+*UU&UFNH\[XDE!88Z\5>DD2&
M)Y9&"1HI9F/0 =30!']DM_\ GBGY4?9+?_GBGY4^&:.X@CFA=7BD4,CJ<A@>
MA%/H A^R6_\ SQ3\J/LEO_SQ3\JFHH A^R6__/%/RH^R6_\ SQ3\JFI ZER@
M8;@,D9Y% $7V2W_YXI^5'V2W_P">*?E4U% $/V2W_P">*?E1]DM_^>*?E4U%
M $/V2W_YXI^5'V2W_P">*?E4A=0RJ6 9N@)Y-.H A^R6_P#SQ3\J/LEO_P \
M4_*IJ* (?LEO_P \4_*C[);_ //%/RJ:B@"'[);_ //%/RI&M+<*2(4Z>E3T
MC_<;Z4 <UO;U-%-HH Z*T_X\X?\ =%35#:?\></^Z*FH **** "BBB@ KD9[
M2#6/B&\&H(LT%A9)+;P.,KO9B"^.A(P!775AZWX>;4KNWU"QOI-/U*W4HDZ*
M&#(>=KJ?O#- $G]A:7:ZY;:C J6EUL:+9%A!.I[,.^.HK*'B#4/^%>3ZSNC^
MVH'(.SY>)"HX^E6]-\.7::G'J6M:JVI74(*VX$0BCASP2%'\1'&:I7'@Z^DT
MBYT:+6!'ILCL\:?9\R+EMVTMGE<^P/O0!8FO=:O?$UWI=E=6]M!%:Q3>:\/F
M,&8G@#(SG'X5EKK_ (B?PS+KS362)9NR26RPD^>$?:QW9^7.#@8-=1;:28-?
MNM3\X,)X(X?+V_=V$\Y]\UGKX78>$KS0_M8S<-*WG>7]W>Y;IGMG'6@"U8ZG
M<7/B?4;%BOV>"WADC&WD%]V<G\!7/OJ-QJ=KH5Q<E3(-<>/Y5P-JF11^@%;=
MQH5XNL'4=-U%+9YH4AN%D@\P,%SAEY&&Y/7(]JKV?A-K33]-M3?&0V=^UV9&
MCYDR6.#SP?FZ_I0!0USQ!J%D]_)_:^EV3VQ/D6+J)9)E R"V&RN[T X'6D$M
MYJ7C#0+Z.Y2%)].:;RC"&P#L++G/?(Y[8JT?"-XJW]M;ZI'%9WDDDC$6P,Z[
M_O 2$]/PSCO5J+P[=6\NBSP7T8FT^W^S2;H<K+&=N<#=\I^7KS0!GZ?KMY')
M9RR+ ME-J5Q9S".,+AMQ$;?F,'US3=2\77-J]])&T"VYO%L+5Y%)"N%)ED;'
M) Z #N*TQX8!\/WVF-=?-<7$EQ',$YB9GWJ<9YP<4'PM'_PC]EIZ73QW5HXG
MCNU4;O.R27(/7))R/>@"EH?B26?7(]->_BU**:-G6XBM6A,;+CY6!XP1T.>U
M=1<6EM=A1<V\4P7D"1 V/SK.L--U);\7FIZI]H9$*1PP1F*(9ZL5W'<WU/%:
M] '#Z*]CI'A'4-6>Q@DDM;FY9,1J&R)&"@'''85>?4-=TC[!>:G<6MQ;7<R0
MS0Q0E# 7X4JV3N /!R!5^T\.0QZ#=Z3=2>?#=23,Y4;2 [$X'N,]:K1^'+^>
M2RCU35A=6EE(LD4:P;&D9?NF1LG..O &30!F:(VJ6*^)KE+B"Y>.\<+'(HA4
MOA?G9\\ #M[>]/T[Q'<CQ)8:>VLV&K0WBOO-M%M\EE7<,,&((/(]:N7?A.:Z
M35[?[>JVE_*+A5\G+1RC;U.<,OR_=([]:=%X;U!M5T[4+O4X&:R=R((+7RXR
M&4J3C<3NZ<Y[=* )/!G_ "";O_L(7/\ Z,-<V;U[/Q+XB8>&9=747"LTB*A\
MO$:\8;GWXKM-$THZ1:30&82^9<2S9"XQO8MC\,TFFZ2=/U'5+LS!Q?3+*%VX
MV84+CWZ4 <AH=\+'3]<\8+8Q6EC<1(8;.)P2S+D;FQPI)(&.HJ>U\77,5W9F
M34[6_%Q*L<MM!:2(8=QQE6/W@#USCBMC_A$X1<ZK&)L:7J:9FM N-DO=T.>,
M^F.HS4EMHVL>9;)>ZXTUK;,&"PP^5)-CH)&#'(]0 ,T <[;76J:/IGBF_2]B
ME>*^("FW ^<E 6Z^AQC\:ZG4=1N+;6]$M8ROE7;RK+E<DA8RPQZ<U3E\+/.N
MLVLEZ/L.I,9=BQ8DBD.WD-G!'R@XQ2Q:!J<NK:;?ZCJT<[6)<+'%;^6K!EVY
M/S'YOT]J ,VWUC7IM"U/67N[9(K47*QP+!DOL+!6+9]1TQVJQ'J>N6<NBW5]
M/:RV^I2)"]O'"5,)9200V>>G.1WJ_#X=:+PS?:/]J!-UY_[W9]WS"3TSSC-3
MW>B&Y@TB/SPO]GSQRD[<[]JD8Z\9S0!8UK4ET?1;O4&C,GD1EP@.-Q[#\\5B
MO?Z[I#6%UJ=Q:W-O=S)!+#%"4,#/]TJV3N /!SBN@U&P@U33KBQN03#.A1\'
M!P?3WK%B\.W\\MDFJ:L+NULI%DBC2#8TC+]TR-DYQUX R: *']I^(KFVUN\M
M[NSBBTZYF2.-X"QF5.<,<C'ID5U.GW7V[3;6[V[?/A27;Z;@#C]:S[?0F@TW
M5[3[0&.H33RAMGW/,&,8SSBM#3[3[#I=K9E]_D0I$6QC=M4#./PH \_EM_[
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M_P ^S_\ ?2_XT 345#YTO_/L_P#WTO\ C1YTO_/L_P#WTO\ C0!-14/G2_\
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M33K86]E;16\()(2) HR?858J*WN8+N$36TT<T3='C<,I_$5+0 4444 %%%%
M!139)(X8VDE=411EF8X _&JG]L:9_P!!&S_[_K_C32;V%=%VBHS<0K")C-&(
MB,ARPVD>N:P[_P ;>']/W!]025Q_#"-Y_3C]:EM+<TA3G/X%<Z"BN%;X@W-\
MQ31-!NKH]G<$#\A_C3?(\?:O_K)[;2XCV7&X?ED_K4>T734W^J37\1J/J_T5
MV=S+-% A>:5(T'\3L /UK OO'/A^PR&OUF<?PP O^HX_6LF+X<17$@EU?5KR
M]?N-V!^N36_8^$]"T[!@TV'</XY!O/YG-%YOI8?+AH;R<O33\SGCX^OM08IH
MF@7-QZ22 X_3_&F_8_'NK_Z^\M],B/\ #'C</RR?UKNU4* %  '0"EHY&]V+
MZS"/\."7KK^>GX'$0?#>UE?S=6U.\OI.^6VC^IJW?_#W0[JS2"WA:T=&!\V,
MDL1W!SU_I7644_9Q[">+KMWYG_7D5K"PMM,LH[2TB$4,8PJC^9]35FBBK.=M
MMW84444""BBB@ HHHH **** "BBB@ HHHH R/$'ARR\167DW*[95'[J91\R'
M^H]JY;2O$%_X5ODT7Q'EK?I;WG4;>V3W'ZBO0*HZMI%GK5B]I>Q!XST/\2GU
M![&HE'7FCN=-*NE'V=17C^*\T74=9$5T8,K#((.012UYS;7NI^ +U;+4-]WH
MDC8BF R8_P##Z?E7H-M<P7EM'<6TJRPR#*NIR"*<97TZDUJ#IV:=XO9_UU):
M***HP"BBB@ HHHH **** "BBF22QPQF2618T7DLQP!^- #Z*Y'5/B%I5H_D6
M*R:A<G@+"/ES]>_X9K.\CQIXG_UTBZ/9-_"O#D?S_E4.HMEJ=4<).W-4]U>?
M^6Y;\;^+VT:,:?8,#>RKEI."(EZ?]]4>!/%<^M1/87J.]U;IN\\#AUZ?-Z-_
M.I+?X;Z+%9RQSF:XGD7!G=L%3Z@=/SS6_HFB6>@Z>MI9IQU>1OO2-ZFI2GS7
M>QK4J894/9P5Y=]OZ]#1HHHK4X HHHH *1_N-]*6D?[C?2@#F**** .BM/\
MCSA_W17$>)I+&S\2?:!);2W1"[[*[@W&;"_+Y3=<GIQD;N37;VG_ !YP_P"Z
M*<\$4DL<KQJTD>2C$<KG@XH Y][)8/%%Q+;^9]IN-.D8L[ECG>, 9Z 9X KE
MW.G2V%F-/C4B"R4:JL2_,%WQ[EDP/O<.2#SC->EX&<X&>F:0(JEB% W=<#K0
M!@^''M)M0U:;3?*.GO)'Y;0@>6SA/G*XX_NYQW%=!2*JHH55"@= !BEH B<S
M[CL2,KV)8@_RINZZ_P"><7_?9_PJ>B@"#==?\\XO^^S_ (4;KK_GG%_WV?\
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M><7_ 'V?\*GHH @W77_/.+_OL_X4;KK_ )YQ?]]G_"IZ* (-UU_SSB_[[/\
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M )^6_P"^5_PH\J;_ )^6_P"^5_PH FHJ'RIO^?EO^^5_PH\J;_GY;_OE?\*
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MZ??SI<RVK(1.L83>KC(RHX!!!'Y5KUGZ7I?]G"9Y+J6[N9V#2SR@ M@8 PH
M  ]*T* (VN(48JTJ!AU!--^U6_\ SVC_ .^JEP/04;1Z"@"+[5;_ //:/_OJ
MC[5;_P#/:/\ [ZJ7:/04;1Z"@"+[5;_\]H_^^J/M5O\ \]H_^^JEVCT%&T>@
MH B^U6__ #VC_P"^J/M5O_SVC_[ZJ7:/04;1Z"@"+[5;_P#/:/\ [ZH^U6__
M #VC_P"^JEVCT%&T>@H B^U6_P#SVC_[ZH^U6_\ SVC_ .^JEVCT%&T>@H B
M^U6__/:/_OJC[5;_ //:/_OJI=H]!1M'H* .1\1>'+>^G&IZ5=1VFJ1G<&5M
MHD/OZ'W_ #K#'Q'U.T_T:[TV%KB+Y)&,A7)'M@UZ5M'H*\D\1^'=9N?$FH3P
M:9<20R2[D=0,$8'O7;AI1J>[5V6USEKJ4/>I]3L?"WC!M?GN8[BVBMA"JL")
M,YR2.X'I72_:K?\ Y[1_]]5Y;X?\*>(C/.\4D^E2*J[6<8$G)XX/;^M;Y_X3
MS3NJVNH1K],G^1I5J,'/W)+T'3JRY??3.S^U6_\ SVC_ .^J/M5O_P ]H_\
MOJN,'CF^LOEU;P]<0^K1@X_4?UK0M/'WAZZP'G>W;TFC(_49%8O#U%K:_IJ:
M*M!]3H_M5O\ \]H_^^J/M5O_ ,]H_P#OJH;74].O0#:WEO-GLC@G\JM[1Z"L
MFFMS1-/8B^U6_P#SVC_[ZH^U6_\ SVC_ .^JEVCT%&T>@I#(OM5O_P ]H_\
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MAXI\4P<W/AAV [Q[O_KUS_5Y=&G\T;^V75/[CN**XC_A84L/_'WH%[%ZX_\
MK@5*GQ*T8\30WD1]#&#_ %H^K5>P>WI]SLJ*YB/Q_P"'Y/\ EYD7_>B(JW%X
MNT2?_5WT9^I _G4.E46\64JD'LS<HJC%JUI/_JI%D_W74_UJ8W6%+>3+@#/
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M %%%% !4,EI;2_ZRWB?_ 'D!J:BBX&9-X=T:?_6:7:$^HB /Z51E\#^'9?\
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M'_"C-U_=A_[Z/^%35G:EK=GI4L45P+AI)0658('E.!C)PH..HH MYNO[L/\
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MX/0=C5AM>TQ-)&J/=HEH1]]\@YSC&#SG/&.M %O-U_=A_P"^C_A1FZ_NP_\
M?1_PJE>^(-.T^X2&XF<,P!8K&S+&#P"Y PH/OBM.@"'-U_=A_P"^C_A1FZ_N
MP_\ ?1_PJ'4M3MM*MEGN3)M9Q&HCC:1BQZ !033=.U>SU7S!;.XDB($D4L;1
MNN>F58 X/K0!8S=?W8?^^C_A1FZ_NP_]]'_"IJ@O+R#3[22ZN9!'#&,LV,_D
M!U/M0 N;K^[#_P!]'_"C-U_=A_[Z/^%44\0Z6VFS:@]SY,$!*R^<C1LAQG!5
M@#G!'&.<UI1NLL:R*<JP##Z&@"/-U_=A_P"^C_A1FZ_NP_\ ?1_PJC-X@TZW
MU#[%)*_F!@C.(F,:,>BLX&T$Y'!/<4ZSU[3K^]DM+>9FE0$C=&RJX!PQ5B,,
M >#C- %S-U_=A_[Z/^%&;K^[#_WT?\*I-K^GB"XFBDDN$MY1%)]FB:4AL9QA
M0<]><=*ETS5[75XY7M?.Q$_EN)86C(; .,, >] %U=VT;\;N^.E#_<;Z4M(_
MW&^E ',4444 =%:?\></^Z*FJ&T_X\X?]T5-0 4444 %%%% !7&+-<S:'/H2
MZ5?FYEDE3S)("L2AI"=^\\8 .?>NSHH X"6PUL>*99$\X3FX)BG\ARODXX!?
M?L QVVYS6WX6@2#S0+'4;>XV*+J2Z9BLDO<KDG/.>1QC%=)10!RVHB>[URU2
M*PO8KBVN0ZOUM6CS\SMVW;20/X@:N6\<>D:EJD_V8Q6FR )Y4> ?O X ]R,U
MNTC*K## $>A% &;KM_-IU@)K:QEO)RX5%CC+["?XB!S@#T^E<W;-+8SMJ*:;
MJ=U]H@DAE+VQ61IBP;)0_=0C@'H-HKMZ* .;;29(-,T-#;A[NWDMTED5<E57
MKS_=!J*Y%Q=^(K/RK"]AGM9SN9N;8Q'.7';>0?3<,XZ9KJ:* "L'5KE]/UZS
MNS9WEQ#]GEC)MH#(02R$9QTZ&MZB@#@M6LM3NK9KM;.:.UN;QII;4Q,[[=BJ
MA9$96Y*YP#QD9I;2SND>R.K6>J73*B_8V@W)Y)WDG>-_RG&SEB>!CUKO** ,
MO7)C#:KFSNYXGRCO9D^;$".J@<^W'2L>'2Y4T+3]UF?/BNX]FY 94@\W<-Q'
M?&"??K7644 0P7*7!F"!AY4AC;<,<C'3VYKB[U[KQ!]HA;3+^!D21;*"2U9(
MP0/O._3+ $ =!GU/'<A57.T 9.3@=32T <_IR'5]3O;VXTZ:&UDABA$5W%M9
MV4LQ)4]AD 'VK.DTS6)-#M(K>"V,<33O);W+,A9M[;. #D#.<>N*[&B@#.T%
M+J+0+".\C2.X2!%9%).,#CKWQU]Z=KD<DV@ZA%$C/(]NX55&2QVG@5?HH Y9
MKFZUE[&.TTZ]MFM296GNX?* ;RV50,]<EOR%<]I^G:TD-PIBO #$OVU%BDC:
M8[EW;6:0[FQNY4#.?<5Z510!DZ''#'I!6TLKNWAW-Y<-V2&Q]&)*C.>#^59=
MA VH:ZUP^G7D4+0&*[BOES&#E=JQ9XQD'..#Q7544 8VC,;&U2VGADC>:ZGV
M#9@ ;V8?0$=*@\1:C=6TL5K:V=Z?/0^;=VUL93&O]U<?Q'MG@=>:WRJD@D D
M=#CI2T <0EM-';RZ3:Z7=I'=W$,\$K1D+'&/+SO)^ZPV$8/)XK;NK KK9DMK
M7"R64P=HP$W2,5QEL=3CJ:W** .6\-0S0W>R"+58;..#9(FH,3B0$;=F>P&[
M...E=3110!S3:C)IFM:JITO4+GSVC:(P6Y9&_=@8W=!R.]<[J&CZS;FRA\N9
MO+M46W\F*200RY);!5U"GE>6R,"O1Z* .5TBV>+7W>\L]0;42[[[O<?(,9^Z
M.NWT^4#(/YU+XH#W$;V0L+]S*@,,UIRK.,X67L%!Q][(.?:NEHH Q/L;PZW8
M7)ME#?9Y3<R1)P7(3J>_0X^E7;B^3^QFOH[6:Y4Q>8L")EWXR!CUJ\1D8-(
M%4*H  & !VH X>*6ZN+J'69].U&2Z@F5YHS:LFV(JZA8@?O;2V3W.2?05?\
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MVK,+A^",L. @.,]SCTZLT>"ZEN=*LYM/GA_LR*1)Y)$Q'(2-H"'^('K7744
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M#%00<$@<<YJ.V\<^+H+"6YO=./EW,*-!<7-H+>&"5W15&1*YDC^?.?E/R^]
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MU2;U_O#\Z-Z_WA^= "U'%;PP&0PQ)&9&WN44#<WJ?4T_>O\ >'YT;U_O#\Z
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MI<-N\;F160G.\KL+')Y)4X)/6@^$/#YUW^VCI5O_ &AO\PS8/+XQNVYV[O\
M:QFMK>O]X?G1O7^\/SH JW6F65[<0SW-NLDL*2)&QSE5< ,/Q %1Q:)IL)MB
MEG&/LUL;6'(R%B.,ISV^5?RJ]O7^\/SHWK_>'YT 85AX*\-Z8)Q9Z/;1BXB:
M"52"P>,G)0@D_+[=!267@CPWIUJ]M:Z3"D4DB2N"S-N*'*9))) /('3VK>WK
M_>'YT;U_O#\Z *]KI]I8RW,EM"L374OG3;<X=\ %L>N *LTF]?[P_.C>O]X?
MG0 M(_W&^E&]?[P_.FLR[&^8=/6@#FJ*** %;[QI*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
6HH **** "BBB@ H[T44 24444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !, *X# 2(  A$! Q$!_\0
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<% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !, *X# 2(  A$! Q$!_\0
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<% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
